Compositions and methods for modulating an immune response

ABSTRACT

The invention provides methods of modulating follicular regulatory T (TFR) cell-mediated immune responses and the use of those methods in the treatment of diseases or conditions such as viral, bacterial, pathogenic, or fungal infections or cancer. Such methods provide for boosting of antibody production through the use of IL-21 to overcome TFR cell suppression of antibody production.

RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.15/778,524, filed May 23, 2018, which is the U.S. National Stage ofInternational Patent Application No. PCT/US2016/063604, filed Nov. 23,2016, which claims the benefit of priority to U.S. Provisional PatentApplication Ser. No. 62/258,876, filed Nov. 23, 2015 and U.S.Provisional Patent Application Ser. No. 62/300,339, filed Feb. 26, 2016.The contents of each of which are hereby incorporated by reference intheir entirety.

BACKGROUND

Regulation of immune responses is central for the prevention ofinflammatory and autoimmune disorders. While downregulation of theimmune system can be achieved by way of immunosuppressive therapy,agents that generally suppress the immune system leave subjectssusceptible to other disorders, including infections and cancers. Ameans for controlling the aberrant activation of an immune response tospecific antigens would be a major advance in the treatment ofautoimmune disorders, graft versus host disease and the side effects ofgene therapy, as it would allow downregulation of the immune responseagainst a particular target antigen, but would otherwise leave theimmune system functional against invading pathogens and tumor associatedantigens. Conversely, methods of specifically improving immunogenicityof specific antigens to which immune responses are desired would be oftremendous benefit in promoting desired immune responses, for example inthe context of vaccination and promoting responsiveness to antigensincluding tumor antigens.

T helper (Th) cells are a class of CD4+ cells that function to regulatethe proliferation of B cells and B cell responses. Th cells play animportance role in humoral immunity and immunopathology. Follicularhelper T cells (TFH) are a recently defined subset of CD4+ T cells thatare essential for helping cognate B cells form and maintain the germinalcenter (GC) reaction, and for development of humoral immune responses.These cells are universally defined by expression of the chemokinereceptor CXCR5, which directs them to the B cell follicles via gradientsof the chemokine CXCL13 1. TFH cells also express the transcriptionfactor Bc16 (which represses Blimp-1/Prdm1) and high levels of thecostimulatory receptor ICOS, which are both critical for theirdifferentiation and maintenance 1-4. In addition, TFH cells secretelarge amounts of IL-21, which aids in GC formation, isotype switchingand plasma cell formation 5. In humans and mice functionally similar TFHcells can be found in secondary lymphoid organs. CXCR5+ TFH cells arealso present in peripheral blood and seen at elevated levels inindividuals with autoantibodies, including systemic lupus erythematosus,myasthenia gravis and juvenile dermatomyositis patients. However, thefunction of these circulating TFH remains unclear 6-9.

Regulatory T cells (Tregs) have pluripotent anti-inflammatory effects onmultiple cell types. In particular they control the activation of innateand adaptive immune cells. Tregs acting in an antigen-specific mannerreduce effector T cell activation and function, for example, aftereffector T cells have successfully mounted an attack against an invadingpathogen, or to suppress reactivity to self-antigen and thereby preventautoimmune disease.

Two subsets of Tregs are classified according to the location at whichthey develop in vivo. Naturally occurring Tregs (nTreg) develop in thethymus and suppress self-reactive immune responses in the periphery,whereas adaptive Tregs (aTreg) develop in the periphery fromconventional CD4+ T cells to ensure tolerance to harmless antigens,including those derived from, for example, food and intestinal flora.

Both subsets of Treg cells are characterized by expression of highlevels of CD25 and the transcription factor Foxp3. Tregs are thought toinhibit the antigen-specific expansion and/or activation ofself-reactive effector T cells and to secrete suppressive cytokines,including TGF or IL-10. Because of their potential to provideantigen-specific immune regulation without generalizedimmunosuppression, Tregs have been contemplated for use in cell-basedtherapy for inflammatory or autoimmune disorders.

T follicular regulatory (TFR) cells are newly defined subset ofCD4+CXCR5+ cells which are positive for the transcription factors FoxP3,Bc16 and Prdm1/Blimp1 and function to inhibit the germinal centerresponse21-23. The present inventors have discovered how TFR cellssuppress antibody production, and how a specific cytokine can overcomethis suppression to boost antibody production. This discovery haselucidated novel approaches to modulating an immune response for use intherapy

SUMMARY

The present inventors have discovered that TFR cells derived from theperipheral blood of a subject are potent inhibitors of TFH mediatedantibody production but do not inhibit other arms of the immune system.Compositions comprising TFR cells may be isolated from the peripheralblood of a subject. The compositions may be enriched for the peripheralblood TFR cells by purifying TFR cells from other PMBCs and optionallysorting for TFR cells based on surface markers. Compositions of TFRcells derived from peripheral blood may also be expanded and/oractivated to produce a clonal population of TFR cells based on theoriginal population of TFR cells derived from the peripheral blood ofthe patient.

The present inventors have discovered that B and TFH cells are changedby TFR suppression. Suppressed TFH cells have defective cytokineproduction but still express TFH program and are metabolicallyreprogrammed. Suppressed B cells have a distinct suppressed genesignature and are metabolically reprogrammed, such that inhibitinggeneral metabolic pathways (e.g., blocking purine/1C metabolic pathway)resembles or recapitulates TFR suppression.

The inventors have also discovered that increasing the ratio of TFRcells to TFH cells in a subject prior to, or during an immune responseby the subject, inhibits antibody production. Therefore, the inventionprovides a method for suppressing an immune response in a subjectwherein suppression of an immune response is desired, comprisingincreasing the ratio of TFR cells to TFH cells by administering acomposition enriched with TFR cells derived from the peripheral blood ofa subject (or an expanded/activated population thereof) or administeringa composition comprising TFR cells having enhanced suppressive activity.

The invention also provides methods of boosting antibody production in asubject comprising contacting a TFR or TFH cell with a specific cytokine(e.g., IL-21, IL-6) to limit TFR suppression of antibody production.

The compositions of TFR cells and TFH cells of the invention are alsouseful as adjuvants as a part of a vaccination regimen. When used inthis manner, the compositions enhance the efficacy of such vaccines.

The invention further provides compositions and methods for enhancing aprotective antibody response in a patient comprising selectivelymodulating TFH or TFR cells with agents (e.g. cytokines like IL-21 orIL-6) in amounts effective to enhance a protective antibody response orboost antibody production or response in a patient.

One aspect of the invention relates to a composition comprising Tfollicular regulatory (TFR) or TFH cells and a cytokine, wherein saidcomposition has enhanced immune activity.

In some embodiments, the enhanced immune activity are characterized by aboost in antibody production in vitro and in vivo as compared to nativeTFR cells.

In some embodiments, the enhanced immune activity is a protectiveantibody response.

In some embodiments, the cytokine is IL-21. In some embodiments, thecytokine is IL-6

Another aspect of the invention relates to a method of preparing acomposition comprising TFR cells having reduced activity comprising thesteps of:

a) obtaining an initial population of cells comprising TFR cells, Tregulatory (Treg) progenitor cells, or both;

b) contacting the cells ex vivo in the presence of a cytokine; and

c) isolating the TFR cells from the population wherein the isolated TFRcells have reduced immune activity.

In some embodiments, the reduced activity results in a boost in antibodyproduction.

In some embodiments, the initial population of cells is isolated fromthe peripheral blood, tissues or organs of one or more subjects.

In some embodiments, the method further comprising sorting TFR cells andTreg progenitor cells from the cell population prior to contacting thecell with the cytokine.

In some embodiments, the method further comprising the step of expandingthe cell population.

Another aspect of the invention relates to a method of modulating animmune response in a subject in need thereof comprising:

administering to the subject a) an effective amount of a compositioncomprising T follicular regulatory (TFR) cells and a cytokine.

In some embodiments, the TFR cells are administered conjointly or incombination with the cytokine.

In some embodiments, the TFR cells are contacted with the cytokine priorto administering to the subject.

In some embodiments, the TFR cells are isolated from the peripheralblood of a subject.

In some embodiments, the TFR cells modulation results in boostedantibody production.

In some embodiments, the method further comprises administering avaccine to the subject.

In some embodiments, the method further comprises co-administering acomposition comprising TFH cells and a vaccine.

In some embodiments, the composition is administered intravenously.

In some embodiments, the subject is afflicted with a disease orcondition selected from the group consisting viral infection, bacterialinfection, pathogenic infection, fungal infection, and cancer.

Another aspect of the invention relates to an adjuvant comprising acomposition of TFH cells and a cytokine having enhanced immune activity.

In some embodiments, the TFH cells are purified from the peripheralblood of a subject.

In some embodiments, the adjuvant further comprises TFH cells purifiedfrom the peripheral blood of a subject, TFH cells having enhancedstimulatory capacity or any combination thereof.

Another aspect of the invention relates to a method of upregulating animmune response in a subject comprising administering to the subject, aneffective amount of the composition comprising T follicular regulatory(TFR) cells and a cytokine.

Another aspect of the invention relates to a vaccine comprising thecomposition comprising T follicular regulatory (TFR) cells and acytokine.

Another aspect of the invention relates to a method of boosting antibodyproduction in a subject in need thereof comprising administering to thesubject the adjuvant comprising a composition of TFR cells and acytokine.

Another aspect of the invention relates to a method of increasing aprotective antibody response in a subject in need thereof comprisingadministering to the subject a first agent capable of modulating TFRcell suppression in an amount effective to decrease TFR cell-mediatedantibody suppression in the subject.

In some embodiments, the method further comprises administering a secondagent capable of modulating a selective TFH receptor in an amounteffective to increase TFH cell-mediated antibody production, wherein theprotective antibody response is increased as compared to the protectiveantibody response in the absence of the first or second agents.

In some embodiments, the second agent is administered conjointly, incombination, or subsequently to the first agent. In some embodiments,the second agent is a vaccine.

In some embodiments, the first agent is a cytokine.

In some embodiments, the subject is afflicted with a disease orcondition selected from the group consisting viral infection, bacterialinfection, pathogenic infection, fungal infection, and cancer.

In some embodiments, the protective antibody response reduces oreliminates the causes or pathogenesis of the disease.

Other objects, features and advantages of the present invention willbecome apparent from the following detailed description. It should beunderstood, however, that the detailed description and the specificexamples, while indicating preferred embodiments of the invention, aregiven by way of illustration only, since various changes andmodifications within the spirit and scope of the invention will becomeapparent to those skilled in the art from this detailed description

BRIEF DESCRIPTION OF FIGURES

The foregoing and other objects, features and advantages of theinvention will be apparent from the following more particulardescription of preferred embodiments of the invention, as illustrated inthe accompanying drawings in which like reference characters refer tothe same parts throughout the different views. The drawings are notnecessarily to scale, emphasis instead being placed upon illustratingthe principles of the invention.

FIG. 1A-FIG. 1T show that suppressed B cells undergo early activation.FIG. 1A is a schematic of suppression assay. FoxP3-GFP reporter micewere immunized with NP-OVA and 7 days later dLN were harvested andCD19+B cells and CD4+CXCR5+ICOS+FoxP3−CD19− TFH were cultured with orwithout CD4+CXCR5+ICOS+FoxP3+CD19− TFR cells in the presence ofanti-CD3/IgM. (FIG. 1B) Class switched IgG1+GL7+B cells (left) andantibody measurements (right) from suppression assays as in (FIG. 1A)cultured for 6 days. B cells are pregated on CD19+IA+CD4−. (FIG. 1C)Proliferation of B cells measured by Cell Trace Violet (CTV) dilutionfrom suppression assays as in (FIG. 1A) cultured for 6 days. B cells arepregated on CD19+IA+CD4− (FIG. 1D) CD69 expression time course on Bcells from suppression assays as in (Panel a). B cells are pregated onCD19+IA+CD4− (FIG. 1E) Cell death in B cells measured by zVAD stainingin suppression assays as in (FIG. 1A). B cells are pregated onCD19+IA+CD4− (FIG. 1F) Somatic hypermutation in B cells in suppressionassays. After culture for 6 days, CD19+IA+CD4− B cells were sorted andsomatic hypermutation was assessed using the ImmunoSeq platform. Errorbars indicate standard error. *p<0.05, **p<0.01, ***p<0.001.

FIG. 2A-FIG. 2H show that suppressed TFH and B cells resemble effectorpopulations except for downregulation of key effector genes. (FIG. 2A)Schematic of experiment. B and TFH sorted from NP-OVA immunizedFoxP3-GFP mice were cultured alone (“Activated”) or with TFR cells(“Suppressed”) sorted from FoxP3-GFP Actin-CFP mice in the presence ofNP-OVA. After 4 days CD19+I−A+CD4−CFP−B and CD4+CD19−I−A-CFP− TFH cellswere sorted and subjected to RNAseq analysis. (FIG. 2B) Principlecomponent analysis of activated and suppressed B and TFH cells. (FIG.2C) Venn diagram of differentially expressed (FDR adjusted p<0.05) genesin activated versus suppressed B and TFH cells. (FIG. 2D) (Left) Volcanoplot showing data from all genes or TFH genes in TFH cells in activatedversus suppressed cultures. (Right) Heat map showing TFH genes inactivated and suppressed TFH cells. (FIG. 2E) Single sample GSEA showingcorrelation of activated B, activated TFH and suppressed TFH cells toImmSig datasets (GSE11924, GSE16697, GSE21380, GSE24574). (FIG. 2F)Expression of B cell function gene transcripts in activated orsuppressed B cells. (FIG. 2G) Volcano plot showing data from all genesor B cell function genes in activated versus suppressed B cells. (FIG.2H) Single sample GSEA showing correlation of activated or suppressed Bcells to ImmSig datasets (GSE12366, GSE12845).

FIG. 3 shows that suppressed TFH cells have defective cytokineproduction but still express TFH program.

FIG. 4 shows the GSEA on genes differentially expressed duringsuppression.

FIG. 5A-FIG. 5E show inhibition of c-MYC inhibits B cells similarly toTFR Cells. (FIG. 5A) Volcano plot showing RNA-seq data from FIG. 2A—FIG.2H with all genes or Myc pathway (Hallmark_MYC_TARGETS_V1) genes inactivated versus suppressed B cells. Significance was measured usingChi2 test. (FIG. 5B) Class switch recombination measured by IgG1+GL7+expression in B cells from suppression assays performed as in FIG.1A-FIG. 1F with the addition of the Myc inhibitor 10058-F4 (F4). (FIG.5C) Class switched IgG antibody levels in culture supernatants fromsuppression assays in (FIG. 5B). (FIG. 5D) Class switch recombinationmeasured by IgG1+GL7+ expression (left) or GL7 expression (right) in Bcells from suppression assays in which control (WT) or Mycoverexpressing (Myc) B cells were cultured with TFH alone or along withTFR cells in the presence of anti-CD3/IgM. (FIG. 5E) Class switched IgGantibody levels in culture supernatants from assays as in (FIG. 5D).

FIG. 6A-FIG. 6G show inhibition of the mTOR/AKT pathways inhibits Bcells similarly as TFR Cells. (FIG. 6A) Volcano plot showing RNA-seqdata from FIG. 2A—FIG. 2H with all genes or mTOR signaling(Hallmark_MTORC1_SIGNALING) genes in activated versus suppressed Bcells. Significance was measured using Chi2 test. (FIG. 6B) Class switchrecombination measured by IgG1+GL7+ expression in B cells fromsuppression assays performed as in FIG. 1A-FIG. 1F with the addition ofthe mTOR inhibitor rapamycin (Rapa). (FIG. 6C) Class switched IgGantibody levels in culture supernatants from suppression assays in (FIG.6B). (FIG. 6D) Class switch recombination measured by IgG1+GL7+expression in B cells from suppression assays performed as in (FIG. 6B)with the addition of the mTOR inhibitor PP242. (FIG. 6E) Class switchedIgG antibody levels in culture supernatants from suppression assays in(FIG. 6D). (FIG. 6F) Class switch recombination measured by IgG1+GL7+expression in B cells from suppression assays performed as in (FIG. 6B)with the addition of an AKT inhibitor (Akt-i). (FIG. 6G) Class switchedIgG antibody levels in culture supernatants from suppression assays in(FIG. 6B).

FIG. 7A-FIG. 7J show TFR cells inhibit multiple metabolic pathways in Bcells. (FIG. 7A) Heat map of average expression of genes from RNAseqdata in metabolic pathways. (FIG. 7B) Schematic of key enzymes inglycolysis, TCA and 1-Carbon metabolism with genes downregulated insuppressed B cells compared to activated B cells and genes upregulatedin suppressed B cells. (FIG. 7C) Glut1 expression in B (left) and TFH(right) cells from activated or suppressed cultures. (FIG. 7D) Glucoseuptake measured in culture supernatants from cultures as in (FIG. 7C).(FIG. 7E) Lactate production measured in culture supernatants fromcultures as in (FIG. 7C). (FIG. 7F) Glutamine uptake measured fromculture supernatants from cultures as in (FIG. 7C). (FIG. 7G) Classswitched IgG antibody levels in culture supernatants from cultures as in(FIG. 7C) with the addition of the glucose analog 2-deoxyglucose (2DG),3-nitropropionic acid (3-NPA) or dichloroacetate (DCA). (FIG. 7H)Volcano plot of activated versus suppressed B cells showing all genes orgenes involved in 1-Carbon/Serine/Purine metabolism. (FIG. 7I) Classswitched antibody levels in supernatants of cocultures as in (FIG. 7C)with the addition of Methotrexate (MTX). (FIG. 7J) Class switchedantibody levels in supernatants of cocultures as in (Panel c) with theaddition of Azathioprine (AZA). *p<0.05, **p<0.01, ***p<0.001.

FIG. 8A-FIG. 8G show TFR suppression results in sustained inhibition andepigenetic changes in B cells. (FIG. 8Aa) Schematic of restimulationassay. FoxP3-GFP mice were immunized with NP-OVA and 7 days later B andTFH cells were sorted and cultured alone or with TFR cells in thepresence of anti-CD3/IgM. After 3 days, B cells from the activatedculture (Act B) or suppressed culture (Supp B) were sorted and culturedwith TFH cells from FoxP3-GFP immunized mice in the presence ofanti-CD3/IgM for 6 days. (FIG. 8B) Intracellular Bc16 and Ki67 in TFHcells from cultures as in (FIG. 8A). (FIG. 8C) Class switched(IgG1+GL7+) B cells were analyzed from cultures as in (FIG. 8A). (FIG.8D) Glut1 expression in B cells from cultures as in (FIG. 8A). (FIG. 8E)Glucose uptake in supernatants from cultures as in (FIG. 8A). (FIG. 8F)Venn diagram showing genes downregulated in B cells upon suppressionfrom RNA-seq data from FIG. 2A—FIG. 2H along with genes showing evidenceof inaccessibility in B cells upon suppression measured by ATAC-seq.(FIG. 8G) (Left) RNA-seq data sorted by ascending ATAC-seq p-value forgenes downregulated in suppressed B cells by RNA-seq and measured to beless accessible by ATAC-seq. (Right) Expression tracks, gene track andpeak track for Aicda and Pou2af1 from ATAC-seq data. *p<0.05, **p<0.01,***p<0.001.

FIG. 9 shows that epigenetic modification of B cells during TFR cellsuppression.

FIG. 10 shows that IL-21 can rescue TFR suppression: antibody productionand metabolism.

FIG. 11A-FIG. 11J show that IL-21 can overcome TFR-mediated suppressionof B cell metabolism and Antibody Production. (FIG. 11A) (Left) B cellproliferation measured by Cell Trace Violet (CTV) dilution from B cellsin cultures of TFH cells alone, TFH and TFR cells, or TFH and TFR cellswith the addition of IL-21. (FIG. 11B) Class switch recombinationmeasured by IgG1+GL7+ staining in B cells from cultures as in (FIG.11A). (FIG. 11C) Antibody production measured in culture supernatantsfrom cultures as in (FIG. 11A). IL-4/IL-21(left) or IL-6 (right) wasadded to some wells. (FIG. 11D) Glut1 expression in B cells fromcultures as in (FIG. 11A). (FIG. 11E) Glucose uptake was measured fromculture supernatants as in (FIG. 11A). (FIG. 11F) Lactate production wasmeasured in culture supernatants as in (FIG. 11A). (FIG. 11G) Antibodyproduction measured in culture supernatants as in (Panel a) with theaddition of 2-deoxyglucose (2DG). (FIG. 11H) Volcano plot showing allgenes or B cell function genes from RNA-seq analysis from sorted B cellsin Suppressed+IL-21 versus Suppressed cultures. (FIG. 11I) CollapsedssGSEA correlation plots for Activated, Suppressed or Suppressed+IL-21 Bcell RNA-seq data. (FIG. 11J) (Left) Ki67 expression in or (Right) totalnumbers of TFR cells from Suppressed or Suppressed+IL-21 cultures as in(FIG. 11B). *p<0.05, **p<0.01, ***p<0.001.

FIG. 12 shows metabolic reprogramming during T_(FR) suppression.

FIG. 13 shows suppressed B cells have an altered metabolic signature.

FIG. 14 shows that IL-21 can rescue T_(FR) suppression: Pou2af1, Aicda,Ighg1, Ighg2c, Mthfd2, Shmt2, Psph, Impdh1, Pgam1, and Metap2 areanalyzed.

FIG. 15 shows the quantification of secreted antibody in cultures as inFIGS. 1A and 1 n a culture including CD4+ICOS-CXCR5-Foxp3+ Treg cells(below plot).

FIG. 16 shows the frequency of IgG1+B cells from cultures as in FIGS. 1Aand 1 n a culture including supernatant of suppressed cultures (T_(FR)sup).

FIG. 17 shows a micrograph of a culture containing B cells, TFH cellsand TFR cells, after 4 d. Scale bar, 5 μm.

FIG. 18 shows proliferation of B cells in cultures as in FIG. 1A,incubated for 4 d with or without lipopolysaccharide (LPS) and IL-4 andT_(FR) cells (key).

FIG. 19 shows the data from flow cytometry (left) of cultures as in FIG.1A of cells pre-gated on TFH cells (CD4+Foxp3−CD19−IA−). Numbersadjacent to outlined areas (left) indicate percentBc16+Ki67+(cell-cycling) T_(FH) cells.

FIG. 20 shows the frequency of Glut1+ cells among B cells from activatedcultures (B cells plus T_(FH) cells), TFR cell-suppressed cultures (Bcells plus T_(FH) cells plus T_(FR) cells), or Treg cell-suppressedcultures (B cells plus T_(FH) cells plus Treg cells) (below plot).

FIG. 21 shows the frequency of Glut1+ cells among B cells cultured withT_(FH) cells only or with T_(FH) cells plus T_(FR) cells (key), gated toindicate CellTrace Violet division peaks (horizontal axis).

FIG. 22 shows the flow cytometry of B cells added to cultures of T_(FH)cells or TFH cells plus TFR cells (left margin) at day 3 and assessed 20h later (left), and frequency of Glut1+ cells among those B cells(right). Numbers in outlined areas (left) indicate percent Glut1+ Bcells.

FIG. 23 shows the frequency of Glut1+ cells among T_(FH) cells incultures as in FIG. 20.

FIG. 24 shows the flow cytometry of cultures as in FIG. 20 in thepresence (+2DG) or absence of 2DG (numbers in plots, as in FIG. 1B)

FIG. 25 shows expression of Shmt1 (top) and Shmt2 (bottom) in B cellsadded to cell-free cultures (Control) or to activated or suppressedcultures (key) at day 3 and assessed 20 h later.

FIG. 26 shows the frequency of T_(FH) cells in cultures as in FIG. 8A.

FIG. 27-FIG. 29 ATAC-seq peaks and ChIA-pet annotated B cell regulomegene tracks for Aicda (FIG. 27), Myc (FIG. 28) and Pou2af1 (FIG. 29);boxes indicate significant downregulation (P<0.05)

FIG. 30 shows the distance of ATAC-seq peaks from TSSs for all peaks orpeaks less accessible in suppressed B cells.

FIG. 31 shows all genes expressed differentially (FDR-adjusted P value,<0.05) in activated B cells versus suppressd B cells (left) or insuppressed B cells rescued with IL-21 versus suppressed B cells (right).

FIG. 32 shows the frequency of IgG1+GL7+B cells in cultures (pre-gatedas CD19+IA+CD4−) of wild-type B cells (WT) or Il21r−/− B cells (21R)cultured with TFH cells alone, TFH and TFR cells, or TFH cells and TFRcells plus IL-21 (below plot).

FIG. 33 shows GL7 expression in B cells from cultures as in FIG. 32.

FIG. 34 shows the frequency of GL7+ cells among B cells from cultures asin FIG. 32.

FIG. 35 shows the Glut1 expression in T_(FR) cells from cultures as inFIG. 11J (left), and frequency of Glut+ T_(FR) cells from cultures(right).

FIG. 36A-FIG. 36C show the Sorting gates for T_(FH) cells, T_(FR) cellsand B cells. FIG. 36A shows a schematic of Suppression assay. FoxP3-GFPreporter mice were immunized with NP-OVA and 7 days later dLN wereharvested and CD19+ B cells and CD4⁺CXCR5⁺ICOS⁺FoxP3⁻CD19⁻T_(FH) cellswere cultured with or without CD4⁺CXCR5⁺ICOS⁺FoxP3⁺CD19⁻T_(FR) cells inthe presence of anti-CD3/IgM. FIG. 36B shows the sort strategy forsorting T_(FH) and T_(FR) cells. FIG. 36C shows the class switch to IgG1in suppression assays in which B and T_(FH) cells were cultured with orwithout TFR cells along with either anti-CD3/IgM or NP-OVA.

FIG. 37A-FIG. 37E show additional characterization of activated andsuppressed B cells based on RNA-seq analysis. FIG. 37A shows a schematicof experiment. B and T_(FH) cells, sorted from NP-OVA immunizedFoxP3^(GFP) mice, were cultured alone (“Activated”) or with T_(FR) cells(“Suppressed”) sorted from FoxP3^(GFP) Actin^(CFP) mice, in the presenceof NP-OVA. After 4 days CD19⁺IA⁺CD4⁻CFP⁻ B and CD4⁺CD19⁻IA⁻CFP⁻T_(FH)cells were sorted and processed for RNA-seq analysis. FIG. 37B shows thesorting gates for B cells. FIG. 75C shows volcano plots showing genes inB and T_(FH) cells in the context of activated or suppressed cultures.FIG. 37D shows the heat map of genes differentially expressed (FDRcorrected p<0.05) in B and T_(FH) cells from activated versus suppressedcultures. FIG. 37E shows genes differentially expressed in both T_(FH)and B cells in activated versus suppressed cultures.

FIG. 38 shows the heat maps of individual genes in metabolic pathways(shown in FIG. 7A) from suppression assays in which B and TFH (Act B) orB, TFH and TFR were cultured.

FIG. 39A-FIG. 39E show additional analysis of altered metabolic pathwaysin TFR cell-suppressed B cells. FIG. 39A shows Glut1 staining in B cellsfor experiments shown in FIG. 4b . FIG. 39B shows (left) Gating ofdivision number for experiments shown in FIG. 4c . (right) IgG1+staining in B cells gated by division number. FIG. 39C shows IgG1+staining in B cells that were added to 3 day cultures and harvested 20hours later as in FIG. 4d . FIG. 39D shows glutamine uptake measuredfrom culture supernatants from cultures as in FIG. 4b .CD4⁺ICOS⁻CXCR5⁻FoxP3⁺T_(reg) cells were added in some conditions. FIG.39A shows IgG1+B cells in culture supernatants from cultures as in FIG.39A with the addition of glutaminolysis inhibitor BPTES.

FIG. 40A-FIG. 40C show expanded analysis of ‘IL-21 rescue’. FIG. 40Ashows the cell count (left), IgG1+ staining (middle) and Glut1expression (right) on B cells from suppression assays in which IL21, IL6or IL4 were added. FIG. 40 B shows the cell count (left), IgG1+ staining(middle) and Glut1 expression (right) on B cells from suppression assaysin which WT or Il21r^(−/−) B cells were cultured as well as IL-21. FIG.40C shows the heat map of genes downregulated in activated versussuppressed B cells, but not rescued with the addition of IL-21

DETAILED DESCRIPTION

U.S. serial application Ser. No. 14/707,596, PCT/US2013/069197, filedNov. 8, 2013, and U.S. provisional application No. 61/724,424, filedNov. 9, 2012, are hereby incorporated by reference in there entirety.

I. Definitions

So that the invention may be more readily understood, certain terms arefirst defined.

T follicular regulatory (TFR) cells as used herein include, but are notlimited to, the following cell surface markers:CD4+ICOS+CXCR5+FoxP3+CD19− or CD4+ICOS+CXCR5+GITR+CD19−, orCD4+ICOS+CXCR5+CD25hiCD19−. In one embodiment, TFR cells have thefollowing cell surface markers: CD4+CXCR5+ICOS+ and at least one surfacemarker selected from: GITR+, CD25hi, CD6, TIGIT, CD162, CD27, CD95, CD9,CD43, CD50, CD45RB, CD102, CD61, CD58, CD196, CD38, CD31, CD15, CD25,CD13, CD66a/c/e, CD11b CD63, CD32, CD97, HLA-HQ, CD150, Siglec-9,Integrinβ7, CD71, CD180, CD218a, CD193, CD235ab, CD35, CD140a, CD158b,CD33, CD210, HLA-G, CD167a, CD119, CX3CR1, CD146, HLA-DR, CD85, CD172b,SSEA-1, CD49c, CD170, CD66b, and CD86. In one embodiment, TFR cells havethe following cell surface markers: CD4+CXCR5+ICOS+ and at least onesurface marker selected from: CD27, CD278 (ICOS), CD150, Siglec-9,CD140a, CD158b, CD33.

T follicular helper (TFH) cells as used herein include, but are notlimited to the following cell surface markers:CD4+ICOS+CXCR5+FoxP3-CD19-. In one embodiment, TFH cells have thefollowing cell surface markers: CD4, CXCR5, ICOS positive and at leastone marker selected from CD163, CD127, CD8a, CD89, CD197, CD161, CD6,CD229, CD96, CD272, CD148, CD107a, CD100, CD82, CD126, CD45RO, CD279,CD5, and CD99 and optionally wherein the TFH cells are negative for oneor more of the following receptors GITR, CD25, CD162, CD27, CD95, CD9,CD43, CD50, CD45RB, CD102, CD61, CD58, CD196, CD38, CD31, CD15, CD25,CD13, CD66a/c/e, CD11b CD63, CD32, CD97, HLA-HQ, CD150, Siglec-9,Integrinβ7, CD71, CD180, CD218a, CD193, CD235ab, CD35, CD140a, CD158b,CD33, CD210, HLA-G, CD167a, CD119, CX3CR1, CD146, HLA-DR, CD85, CD172b,SSEA-1, CD49c, CD170, CD66b, and CD86. In one embodiment, TFH cells havethe following cell surface markers: CD4, CXCR5, ICOS positive and atleast one marker selected from CD163, CD127, CD161, CD6, CD229, CD272,CD100, CD126, PD-1 (CD279), and optionally wherein the TFH cells arenegative for one or more of the following receptors GITR, CD25, CD162,CD27, CD95, CD9, CD43, CD50, CD45RB, CD102, CD61, CD58, CD196, CD38,CD31, CD15, CD25, CD13, CD66a/c/e, CD11b CD63, CD32, CD97, HLA-HQ,CD150, Siglec-9, Integrinβ7, CD71, CD180, CD218a, CD193, CD235ab, CD35,CD140a, CD158b, CD33, CD210, HLA-G, CD167a, CD119, CX3CR1, CD146,HLA-DR, CD85, CD172b, SSEA-1, CD49c, CD170, CD66b, and CD86.

In one embodiment, TFH cells have the following cell surface markers:CD4, CXCR5, ICOS positive and at least one marker selected from CD163,CD127, CD161, CD6, CD229, CD272, CD100, CD126, PD-1 (CD279), andoptionally wherein the following markers are expressed a lower levels onTFH cells as compared to the levels of expression on TFR cells whereinsuch receptors are selected from: GITR, CD25, CD162, CD27, CD95, CD9,CD43, CD50, CD45RB, CD102, CD61, CD58, CD196, CD38, CD31, CD15, CD25,CD13, CD66a/c/e, CD11b CD63, CD32, CD97, HLA-HQ, CD150, Siglec-9,Integrinβ7, CD71, CD180, CD218a, CD193, CD235ab, CD35, CD140a, CD158b,CD33, CD210, HLA-G, CD167a, CD119, CX3CR1, CD146, HLA-DR, CD85, CD172b,SSEA-1, CD49c, CD170, CD66b, and CD8.

T regulatory cells (Tregs) as used herein include, but are not limitedto the following cell surface markers: CD4+GITR+CXCR5− orCD4+FoxP3+CXCR5− or CD4+CD25hi CXCR5−.

Populations of TFH or TFR cells referred to herein as “isolated” orpurified” from blood refers to cells that have been removed from thebody as part of a sample taken from the peripheral blood, organs ortissues of a subject. “Isolated” and “purified” cell compositions mayfurther be enriched for the desired cell type via known procedures forseparating desired cell types from other cell populations in a sampleincluding cell sorting. As used herein” enriched” means that theresulting sample comprises more of the desired cell type than other celltypes in the sample.

The terms “inhibit”, “inhibition, “suppress” and “suppression” in termsof an immune response includes the decrease, limitation or blockage of,for example a particular action, function or interaction (e.g. antibodysuppression).

The terms “enhance”, “promote” or “stimulate” in terms of an immuneresponse includes an increase, facilitation, proliferation, for examplea particular action, function or interaction associated with an immuneresponse (e.g. increase in antibody production).

As used herein, the term “modulate” includes up-regulation anddown-regulation, e.g., enhancing or inhibiting an immune response. Theterm “modulate” when used with regard to modulation of a receptorincludes up-regulation or down-regulation of the biological activityassociated with that receptor when the receptor is activated, forexample, by its ligand or inhibited, for example, with a blockingantibody.

As used herein, the term “immune cell” refers to cells that play a rolein the immune response Immune cells are of hematopoietic origin, andinclude lymphocytes, such as B cells and T cells; natural killer cells;myeloid cells, such as monocytes, macrophages, eosinophils, mast cells,basophils, and granulocytes.

As used herein, the term “T cell” includes CD4+ T cells and CD8+ Tcells. The term “antigen presenting cell” includes professional antigenpresenting cells (e.g., B lymphocytes, monocytes, dendritic cells,Langerhans cells) as well as other antigen presenting cells (e.g.,keratinocytes, endothelial cells, astrocytes, fibroblasts,oligodendrocytes).

The term “native” cells or “wild-type” cells as used herein withreference to, for example, TFR cells, TFH cells or other cells, meansthat the cells are essentially phenotypically and functionally the sameas those cells of the same cell-type generally found at the originalsource of the native or wild type cells, such as, for example, TFR cellsnormally found in the blood, organs or tissue of a subject.

The term TFR cells with “enhanced suppressive capacity” or “enhancedimmune suppressive activity” or “enhanced regulatory capacity” refers toTFR cells that have been modulated in such a way (for instance activatedduring PD-1 blockade) so they are more potent in their ability toinhibit B cell responses Enhanced immune suppressive activity may bemeasured by standard in vivo and in vitro assays such as antibodysuppression assays as are known in the art and described herein.

The term TFH cells with “enhanced stimulatory capacity”, “enhancedimmune stimulatory capacity” or “enhanced antibody stimulatory capacity”refers to TFH cells that have been modulated in such a way (for instanceactivated during PD-1 blockade or activated in the presence of IL-21) sothey have more potent ability to stimulate B cell responses. Enhancedstimulatory capacity may be measured, for example, by the novel in vivoand in vitro antibody proliferation assays of the invention as describedherein.

As used herein, the term “immune response” includes T cell mediatedand/or B cell mediated immune responses and include those immuneresponses that are mediated by TFR cells or TFH cells. Exemplary immuneresponses include T cell responses, e.g., cytokine production, andcellular cytotoxicity. In addition, the term immune response includesimmune responses that are indirectly affected by T cell activation,e.g., antibody production (humoral responses) and activation of cytokineresponsive cells, e.g., macrophages.

A “subject” is preferably a human subject but can also be any mammal,including an animal model, in which modulation of an autoimmune reactionis desired.

Mammals of interest include, but are not limited to: rodents, e.g. mice,rats; livestock, e.g. pigs, horses, cows, etc., pets, e.g. dogs, cats;and primates. A subject may also be a donor of peripheral blood T cellswho is not the subject in which modulation of an autoimmune reaction isdesired also referred to herein as a “healthy donor”. A subject may alsobe referred to herein as a “patient”.

The terms “treatment” “treat” and “treating” encompasses alleviation,cure or prevention of at least one symptom or other aspect of adisorder, disease, illness or other condition (collectively referred toherein as a “condition”), or reduction of severity of the condition, andthe like. A composition of the invention need not affect a completecure, or eradicate every symptom or manifestation of a disease, toconstitute a viable therapeutic agent. As is recognized in the pertinentfield, drugs employed as therapeutic agents may reduce the severity of agiven disease state, but need not abolish every manifestation of thedisease to be regarded as useful therapeutic agents. Beneficial ordesired clinical results include, but are not limited to, alleviation ofsymptoms, diminishment of extent of disease, stabilization (i.e., notworsening) of disease, delay or slowing of disease progression,amelioration or palliation of the disease state, remission (whetherpartial or total, whether detectable or undetectable) and prevention ofrelapse or recurrence of disease. Similarly, a prophylacticallyadministered treatment need not be completely effective in preventingthe onset of a condition in order to constitute a viable prophylacticagent. Simply reducing the impact of a disease (for example, by reducingthe number or severity of its symptoms, or by increasing theeffectiveness of another treatment, or by producing another beneficialeffect), or reducing the likelihood that the disease will occur orworsen in a subject, is sufficient.

“Treatment” can also mean prolonging survival as compared to expectedsurvival if not receiving treatment. In one embodiment, an indicationthat a therapeutically effective amount of a composition has beenadministered to the patient is a sustained improvement over baseline ofan indicator that reflects the severity of the particular disorder.

By a “therapeutically effective amount” of a composition of theinvention is meant an amount of the composition which confers atherapeutic effect on the treated subject, at a reasonable benefit/riskratio applicable to any medical treatment. The therapeutic effect issufficient to “treat” the patient as that term is used herein.

As used herein, “cell therapy” is a method of treatment involving theadministration of live cells.

“Adoptive immunotherapy” is a treatment process involving removal ofcells from a subject, the processing of the cells in some manner ex-vivoand the infusion of the processed cells into the same subject as atherapy.

As used herein, a vaccine is a composition that provides protectionagainst a viral infection, cancer or other disorder or treatment for aviral infection, cancer or other disorder. Protection against a viralinfection, cancer or other disorder will either completely preventinfection or the tumor or other disorder or will reduce the severity orduration of infection, tumor or other disorder if subsequently infectedor afflicted with the disorder. Treatment will cause an amelioration inone or more symptoms or a decrease in severity or duration. For purposesherein, a vaccine results from co-infusion (either sequentially orsimultaneously) of an antigen and a composition of cells produced by themethods herein. As used herein, amelioration of the symptoms of aparticular disorder by administration of a particular composition refersto any lessening, whether permanent or temporary, lasting or transientthat can be attributed to or associated with administration of thecomposition.

As used herein a “vaccination regimen” means a treatment regimen whereina vaccine comprising an antigen and/or adjuvant is administered to asubject in combination with for example, composition of the inventioncomprising TFR cells and/or TFH cells, simultaneously, in eitherseparate or combined formulations, or sequentially at different timesseparated by minutes, hours or days, but in some way act together toprovide the desired enhanced immune response to the vaccine in thesubject as compared to the subject's immune response in the absence of aTFR and/or TFH composition in accordance with the invention.

The term “adjuvant” is used in its broadest sense as any substance whichenhances, increases, upwardly modulates or otherwise facilitates animmune response to an antigen. The immune response may be measured byany convenient means such as antibody titre or level of cell-mediatedresponse.

“Immune-related disease” means a disease in which the immune system isinvolved in the pathogenesis of the disease. Subsets of immune-relateddiseases are autoimmune diseases. Autoimmune diseases include, but arenot limited to, rheumatoid arthritis, myasthenia gravis, multiplesclerosis, psoriasis, systemic lupus erythematosus, autoimmunethyroiditis (Hashimoto's thyroiditis), Graves' disease, inflammatorybowel disease, autoimmune uveoretinitis, polymyositis, and certain typesof diabetes. Other immune-related diseases are provided infra. In viewof the present disclosure, one skilled in the art can readily perceiveother autoimmune diseases treatable by the compositions and methods ofthe present invention.

A disease or condition wherein modulation of, and preferably selectivemodulation of, TFR cells and/or TFH cells is therapeutic, includesdiseases wherein suppression of a pathogenic antibody response isdesired and diseases where enhancement of a protective antibody responseis desired. In some instances, for example, in a disease in whichsuppression of a pathogenic antibody response is therapeutic, it iscontemplated herein that the disease may be treated by selectivelyup-regulating TFR cell-mediated antibody suppression whilesimultaneously selectively down-regulating TFH cell-mediated immuneresponse.

Examples of diseases or conditions wherein suppression of a pathologicalantibody response is desired include diseases in which antibodiescontribute to, or are primarily responsible for pathogenesis. Suchdiseases or conditions in which antibodies contribute to and/or areprimarily responsible for pathogenesis include, but are not limited to,diabetes (Type 1), multiple sclerosis, systemic lupus erythematosus,allergy, asthma, multiple sclerosis, myasthenia gravis, lupuserythematosus, autoimmune hemolytic, scleroderma and systemic sclerosis,Sjogren's syndrom, undifferentiated connective tissue syndrome,antiphospholipid syndrome, vasculitis (polyarteritis nodosa, allergicgranulomatosis and angiitis, Wegner's granulomatosis, hypersensitivityvasculitis, polymyositis systemic lupus erythematosus, collagendiseases, autoimmune hepatitis, primary (autoimmune) sclerosingcholangitis or other hepatic diseases, thyroiditis, glomerulonephritis,Devic's disease, autoimmune throbocytopenic purpura, pemphigus vulgaris,vasculitis caused by ANCA, Goodpasture's syndrome, rheumatic fever,Grave's disease (hyperthyroidism), insulin resistant diabetes,pernicious anemia, celiac disease, hemolytic disease of the newborn,cold aggutinin disease, IgA nephropathology, glomerulonephritis(including post-streptococcal), primary biliary cirrhosis, and serumsickness. In one embodiment diseases in which pathogenic antibodiescontribute to and/or are primarily responsible for pathogenesis areselected from multiple sclerosis, systemic lupus erythematosus, allergy,myasthenia gravis, collagen diseases, glomerulonephritis, Devic'sdisease, vasculitis caused by ANCA, and celiac disease.

Examples of diseases or conditions wherein enhancement of a protectiveantibody response is desired includes those diseases in which thepresence of a robust antibody response reduces or eliminates the causesor pathogenesis of the disease. Examples of diseases or conditionsbenefiting from a protective antibody response include, but are notlimited to viral, pathogenic, bacterial, or fungal infections andcancer.

Viral infectious diseases including human papilloma virus (HPV),hepatitis A Virus (HAV), hepatitis B Virus (HBV), hepatitis C Virus(HCV), Zika Virus, retroviruses such as human immunodeficiency virus(HIV-1 and HIV-2), herpes viruses such as Epstein Barr Virus (EBV),cytomegalovirus (CMV), HSV-1 and HSV-2, influenza virus, Hepatitis A andB, FIV, lentiviruses, pestiviruses, West Nile Virus, measles, smallpox,cowpox, ebola, coronavirus, retrovirus, herpesvirus, potato S virus,simian Virus 40 (SV40), Mouse Mammary Tumor Virus (MMTV) promoter,Moloney virus, ALV, Cytomegalovirus (CMV), Epstein Barr Virus (EBV), orRous Sarcoma Virus (RSV). In addition, bacterial, fungal and otherpathogenic diseases are included, such as Aspergillus, Brugia, Candida,Chikungunya, Chlamydia, Coccidia, Cryptococcus, Dengue, Dirofilaria,Gonococcus, Histoplasma, Leishmania, Mycobacterium, Mycoplasma,Paramecium, Pertussis, Plasmodium, Pneumococcus, Pneumocystis, P. vivaxin Anopheles mosquito vectors, Rickettsia, Salmonella, Shigella,Staphylococcus, Streptococcus, Toxoplasma and Vibriocholerae. Exemplaryspecies include Neisseria gonorrhea, Mycobacterium tuberculosis, Candidaalbicans, Candida tropicalis, Trichomonas vaginalis, Haemophilusvaginalis, Group B Streptococcus sp., Microplasma hominis, Hemophilusducreyi, Granuloma inguinale, Lymphopathia venereum, Treponema pallidum,Brucella abortus. Brucella melitensis, Brucella suis, Brucella canis,Campylobacter fetus, Campylobacter fetus intestinalis, Leptospirapomona, Listeria monocytogenes, Brucella ovis, Chlamydia psittaci,Trichomonas foetus, Toxoplasma gondii, Escherichia coli, Actinobacillusequuli, Salmonella abortus ovis, Salmonella abortus equi, Pseudomonasaeruginosa, Corynebacterium equi, Corynebacterium pyogenes,Actinobaccilus seminis, Mycoplasma bovigenitalium, Aspergillusfumigatus, Absidia ramosa, Trypanosoma equiperdum, Clostridium tetani,Clostridium botulinum; or, a fungus, such as, e.g., Paracoccidioidesbrasiliensis; or other pathogen, e.g., Plasmodium falciparum. Alsoincluded are National Institute of Allergy and Infectious Diseases(NIAID) priority pathogens. These include Category A agents, such asvariola major (smallpox), Bacillus anthracis (anthrax), Yersinia pestis(plague), Clostridium botulinum toxin (botulism), Francisella tularensis(tularaemia), filoviruses (Ebola hemorrhagic fever, Marburg hemorrhagicfever), arenaviruses (Lassa (Lassa fever), Junin (Argentine hemorrhagicfever) and related viruses); Category B agents, such as Coxiellaburnetti (Q fever), Brucella species (brucellosis), Burkholderia mallei(glanders), alphaviruses (Venezuelan encephalomyelitis, eastern &western equine encephalomyelitis), ricin toxin from Ricinus communis(castor beans), epsilon toxin of Clostridium perfringens; Staphylococcusenterotoxin B, Salmonella species, Shigella dysenteriae, Escherichiacoli strain O157:H7, Vibrio cholerae, Cryptosporidium parvum; Category Cagents, such as nipah virus, hantaviruses, yellow fever in Aedesmosquitoes, and multidrug-resistant tuberculosis; helminths, such asSchistosoma and Taenia; and protozoa, such as Leishmania (e.g., L.mexicana) in sand flies, Plasmodium, Chagas disease in assassin bugs.

Bacterial pathogens include, but are not limited to, bacterialpathogenic gram-positive cocci, which include but are not limited to:pneumococci; staphylococci; and streptococci. Pathogenic gram-negativecocci include: meningococci; and gonococci. Pathogenic entericgram-negative bacilli include: enterobacteriaceae; pseudomonas,acinetobacteria and eikenella; melioidosis; salmonella; shigellosis;hemophilus; chancroid; brucellosis; tularemia; yersinia (pasteurella);streptobacillus moniliformis and spirilum; Listeria monocytogenes;erysipelothrix rhusiopathiae; diphtheria; cholera; anthrax; anddonovanosis (granuloma inguinale). Pathogenic anaerobic bacteriainclude; tetanus; botulism; other clostridia; tuberculosis; leprosy; andother mycobacteria. Pathogenic spirochetal diseases include: syphilis;treponematoses: yaws, pinta and endemic syphilis; and leptospirosis.Other infections caused by higher pathogen bacteria and pathogenic fungiinclude: actinomycosis; nocardiosis; cryptococcosis, blastomycosis,histoplasmosis and coccidioidomycosis; candidiasis, aspergillosis, andmucormycosis; sporotrichosis; paracoccidiodomycosis, petriellidiosis,torulopsosis, mycetoma and chromomycosis; and dermatophytosis.Rickettsial infections include rickettsial and rickettsioses. Examplesof mycoplasma and chlamydial infections include: Mycoplasma pneumoniae;lymphogranuloma venereum; psittacosis; and perinatal chlamydialinfections. Pathogenic protozoans and helminths and infectionseukaryotes thereby include: amebiasis; malaria; leishmaniasis;trypanosomiasis; toxoplasmosis; Pneumocystis carinii; giardiasis;trichinosis; filariasis; schistosomiasis; nematodes; trematodes orflukes; and cestode (tapeworm) infections. While not a disease orcondition, enhancement of a protective antibody response is alsobeneficial in a vaccine or as part of a vaccination regimen as isdescribed herein.

The term “cancer” as used herein refers to an abnormal growth of cellswhich tend to proliferate in an uncontrolled way and, in some cases, tometastasize (spread). The types of cancer include, but is not limitedto, solid tumors (such as those of the bladder, bowel, brain, breast,endometrium, heart, kidney, lung, uterus, lymphatic tissue (lymphoma),ovary, pancreas or other endocrine organ (thyroid), prostate, skin(melanoma or basal cell cancer) or hematological tumors (such as theleukemias and lymphomas) at any stage of the disease with or withoutmetastases.

Additional non-limiting examples of cancers include, acute lymphoblasticleukemia, acute myeloid leukemia, adrenocortical carcinoma, anal cancer,appendix cancer, astrocytomas, atypical teratoid/rhabdoid tumor, basalcell carcinoma, bile duct cancer, bladder cancer, bone cancer(osteosarcoma and malignant fibrous histiocytoma), brain stem glioma,brain tumors, brain and spinal cord tumors, breast cancer, bronchialtumors, Burkitt lymphoma, cervical cancer, chronic lymphocytic leukemia,chronic myelogenous leukemia, colon cancer, colorectal cancer,craniopharyngioma, cutaneous T-Cell lymphoma, embryonal tumors,endometrial cancer, ependymoblastoma, ependymoma, esophageal cancer,ewing sarcoma family of tumors, eye cancer, retinoblastoma, gallbladdercancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor,gastrointestinal stromal tumor (GIST), gastrointestinal stromal celltumor, germ cell tumor, glioma, hairy cell leukemia, head and neckcancer, hepatocellular (liver) cancer, Hodgkin lymphoma, hypopharyngealcancer, intraocular melanoma, islet cell tumors (endocrine pancreas),Kaposi sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngealcancer, leukemia, Acute lymphoblastic leukemia, acute myeloid leukemia,chronic lymphocytic leukemia, chronic myelogenous leukemia, hairy cellleukemia, liver cancer, lung cancer, non-small cell lung cancer, smallcell lung cancer, Burkitt lymphoma, cutaneous T-cell lymphoma, Hodgkinlymphoma, non-Hodgkin lymphoma, lymphoma, Waldenstrom macroglobulinemia,medulloblastoma, medulloepithelioma, melanoma, mesothelioma, mouthcancer, chronic myelogenous leukemia, myeloid leukemia, multiplemyeloma, nasopharyngeal cancer, neuroblastoma, non-Hodgkin lymphoma,non-small cell lung cancer, oral cancer, oropharyngeal cancer,osteosarcoma, malignant fibrous histiocytoma of bone, ovarian cancer,ovarian epithelial cancer, ovarian germ cell tumor, ovarian lowmalignant potential tumor, pancreatic cancer, papillomatosis,parathyroid cancer, penile cancer, pharyngeal cancer, pineal parenchymaltumors of intermediate differentiation, pineoblastoma and supratentorialprimitive neuroectodermal tumors, pituitary tumor, plasma cellneoplasm/multiple myeloma, pleuropulmonary blastoma, primary centralnervous system lymphoma, prostate cancer, rectal cancer, renal cell(kidney) cancer, retinoblastoma, rhabdomyosarcoma, salivary glandcancer, sarcoma, Ewing sarcoma family of tumors, sarcoma, kaposi, Sezarysyndrome, skin cancer, small cell Lung cancer, small intestine cancer,soft tissue sarcoma, squamous cell carcinoma, stomach (gastric) cancer,supratentorial primitive neuroectodermal tumors, T-cell lymphoma,testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroidcancer, urethral cancer, uterine cancer, uterine sarcoma, vaginalcancer, vulvar cancer, Waldenstrom macroglobulinemia, Wilms tumor.

An agent that is an “antagonist” of a cell surface receptor on a TFHcell or a TFR cell is an agent which down regulates or blocks thebiological function of the cell surface receptor. As used herein, anagent which is an “antagonist” includes agents that bind or otherwiseinterfere with ligands of cell surface receptor thereby blocking theability of the ligand to bind to the cell surface receptor anddown-regulate or prevent the biological function of the cell surfacereceptor.

An agent that is an “agonist” of a cell surface receptor on a TFH cellor a TFR cell is an agent which upregulates or increases the biologicalfunction of the cell surface receptor.

II. Starting Population of Cells

In one embodiment TFR cells and TFR precursor cells, for example, Tregulatory (Treg) progenitor cells are derived from a mixed cellpopulation containing such cells (e.g. from peripheral blood, tissue ororgans). Preferably the mixed cell population containing TFR cells orTFR cell precursors is enriched such that TFR cells or TFR cellprecursors comprise more TFR cells than other cell types in thepopulation. In one embodiment, an enriched composition of TFR cells is acomposition wherein the TFR cells make up greater than about 50% (e.g.,55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, 99.5%, 99.9% ormore) of the cell population in the composition. In some embodiments,the TFR cells comprise about 90%, 95%, 98%, 99%, 99.5%, 99.9% or more ofthe cells in the composition, and such compositions are referred toherein as “highly purified” or “substantially homogenous” TFR cellcompositions.

While a starting population of TFR cells is described above, it isunderstood that similar procedures may be applied to obtaining astarting population of TFH cells.

Accordingly in some embodiments a mixed cell population containing TFHis enriched such that the composition comprises more TFH cells thanother cell types in the population. In one embodiment, an enrichedcomposition of TFH cells is a composition wherein the TFH cells make upgreater than about 50% (e.g., 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%,95%, 98%, 99%, 99.5%, 99.9% or more) of the cell population in thecomposition. In some embodiments, the TFH cells comprise about 90%, 95%,98%, 99%, 99.5%, 99.9% or more of the cells in the composition, and suchcompositions are referred to herein as “highly purified” or“substantially homogenous” TFH cell compositions. In some embodiments,TFR cells or TFH cells are enriched from a population of cells prior toan activating and/or expanding step. In some embodiments TFR cells orTFH cells are enriched from a population of cells after the activatingand/or expanding step.

Such highly purified or substantially homogenous populations of TFRcells or TFH cells may be used for in-vivo and in-vitro diagnoses andexamination of TFR cell-mediated, or TFH cell-mediated diseases.

TFR cells can be enriched by targeting for selection of cell surfacemarkers specific for immune suppressive TFR cells and separating usingautomated cell sorting such as fluorescence-activated cell sorting(FACS), solid-phase magnetic beads, etc. To enhance enrichment, positiveselection may be combined with negative selection against cellscomprising surface makers specific to non-T-regulatory cell types, suchas depletion of CD8, CD11b, CD16, CD19, CD36 and CD56-bearing cells.

In one embodiment TFR cells are sorted via flow cytometry based onsurface markers of CD4+CXCR5+ICOS+GITR+, or CD4+CXCR5+ICOS+CD25+. In oneembodiment, TFR cells are sorted via flow cytometry based on thefollowing cell surface markers: CD4+CXCR5+ICOS+ and at least one surfacemarker selected from one or more of: GITR+, CD25hi, TIGIT, CD6, CD162,CD27, CD95, CD9, CD43, CD278, CD50, CD45RB, CD102, CD61, CD58, CD196,CD38, CD31, CD15, CD25, CD13, CD66a/c/e, CD11b CD63, CD32, CD97, HLA-HQ,CD150, Siglec-9, Integrinβ7, CD71, CD180, CD218a, CD193, CD235ab, CD35,CD140a, CD158b, CD33, CD210, HLA-G, CD167a, CD119, CX3CR1, CD146,HLA-DR, CD85, CD172b, SSEA-1, CD49c, CD170, CD66b, and CD86.

TFH cells may be sorted based on surface markers of CD4, CXCR5, ICOSpositive; GITR negative, CD25 negative. In one embodiment, TFH cells aresorted via flow cytometry based on the following cell surface markers:CD4, CXCR5, ICOS positive and at least one marker selected from: CD163,CD127, CD8a, CD89, CD197, CD161, CD6, CD229, CD96, CD272, CD148, CD107a,CD100, CD82, CD126, CD45RO, CD279, CD5, and CD99, and optionally whereinthe TFH cells are negative for one or more of the following receptorsGITR, CD25, CD162, CD27, CD95, CD9, CD43, CD50, CD45RB, CD102, CD61,CD58, CD196, CD38, CD31, CD15, CD25, CD13, CD66a/c/e, CD11b CD63, CD32,CD97, HLA-HQ, CD150, Siglec-9, Integrinβ7, CD71, CD180, CD218a, CD193,CD235ab, CD35, CD140a, CD158b, CD33, CD210, HLA-G, CD167a, CD119,CX3CR1, CD146, HLA-DR, CD85, CD172b, SSEA-1, CD49c, CD170, CD66b, andCD86.

It is believed that these sorting methodologies also contribute to theenhanced functionality of TFH cells and TFR cells alone or incombination with activating such cells in the presence of an antagonistof cytokines or metabolic modulators.

In one embodiment, an initial population of TFR cells may also beisolated from the peripheral blood of a subject and further enriched forTFR cells. In one embodiment, an initial population of TFH cells mayalso be isolated from the peripheral blood of a subject and furtherenriched for TFH cells. Methods of purifying TFR cells or TFH cells fromother PBMCs in the blood, using methods such as differentialsedimentation through an appropriate medium, e.g. Ficoll-Hypaque[Pharmacia Biotech, Uppsala, Sweden], and/or methods of cell sorting,are well known and examples of such methods are described herein.

In one embodiment the invention provides a composition of TFR cellsderived from the peripheral blood of a subject (also referred to hereinas “blood TFR cells”) wherein the composition comprises about 90%, 95%,98%, 99%, 99.5%, 99.9% or more of the cells in the composition.

In one embodiment the invention provides a composition of TFH cellsderived from the peripheral blood of a patient (also referred to hereinas “blood TFH cells”) wherein the composition comprises about 90%, 95%,98%, 99%, 99.5%, 99.9% or more of the cells in the composition. Suchhigh purity compositions of blood TFR cells or blood TFH cells may beused directly in methods of modulating the immune system as describedherein. Alternatively such compositions may be further activated and/orexpanded prior to use in modulating the immune system as describedherein.

III. Activation/Expansion of Starting Population of Cells

In one embodiment, the activation of a starting cell population isachieved by contacting the starting population of TFH cells or TFR cellswith T cell stimulatory composition and/or in the presence of cytokinessuch as IL-21 and IL-6 or metabolic modulators. The activating step mayfurther include an expanding step or the cell population may be expandedseparately from the activating step. If an expanding step is desired,the cells are preferably expanded at least 50-fold, and preferably atleast 100, 200, 300, 500 and 800-fold.

Exemplary metabolic modulators include but are not limited to2-deoxyglucose, metformin, methotrexate, azathioprine, rapamycin,dichloroacetate, lonidamine, alpha-tocopheryl succinate, methyljasmonate, betulinic acid, and resveratrol.

Preferred stimulatory compositions stimulate the T cells by binding andactivating the T cell receptor complex on the cells. In one embodiment,stimulatory compositions may include agents capable of binding andactivating selective TFR and/or selective TFH receptors as describedherein. In one embodiment the stimulatory compositions comprisephysiological antigen presenting cells (APCs), such as CD19+B cells(preferably autologous from blood) a TCR/CD3 activator such as amultivalent antibody or ligand for TCR/CD3; a TCR costimulator activatorsuch as multivalent antibody or ligand for CD28, GITR, CD5, ICOS, OX40or CD40L; and optionally an interleukin such as IL-2, IL-21 or IL-6. Inone embodiment, the TCR/CD3 activator is an anti-CD3 antibody, and theTCR costimulator activator is an anti-CD28 antibody. The anti-CD3 andanti-CD28 antibodies are optionally immobilized on beads as are known inthe art and provided in a cell:bead ratio of between 1:1 and 1:2.

In certain embodiments, the stimulatory composition may further includeone or more additional agents, e.g., a costimulatory agent, a secondregulatory T cell stimulatory agent, or agents that generally promotethe survival and/or growth of T cells.

In certain embodiments, the costimulatory agent is an antibody or ligandspecific for a T cell costimulator, such as CD28 or ICOS, as describedbelow. In particular embodiments, the costimulatory agent is an agonistantibody, such as an agonist antibody which binds to CD28. Thestimulatory composition alternatively comprises a second regulatory Tcell stimulatory agent. Exemplary stimulatory agents include granulocytecolony stimulating factor, interleukins such as IL-2, IL-6, IL-7, IL-13,and IL-15, and hepatocyte growth factor (HGF).

In particular embodiments, one or more components of the stimulatorycomposition is immobilized on a substrate, such as a cell or bead. Cellssuitable for use as substrates include artificial antigen-presentingcells (AAPCs) (Kim, J V et al, Nat Biotechnol. April 2004; 22(4):403-10;and Thomas, A K et al, Clin Immunol. December 2002; 105(3):259-72).Beads can be plastic, glass, or any other suitable material, typicallyin the 1-20 micron range.

Examples of PD-1 and PD-1 ligand antagonists are disclosed in U.S. Pat.No. 7,722,868, incorporated herein by reference. Suitable PD-1 and PD-1ligand antagonists include a PD1-ligand antibody, an anti-PD-1 antibody,a peptide or a small molecule wherein the agent inhibits the interactionbetween PD-1 and a PD-1 ligand. Other examples of PD-1 or PD-1 ligandantagonists are disclosed, for example in U.S. Pat. Nos. 8,168,757;8,114,845; 8,008,449; 7,595,048; 7,488,802; and 7,029,674.

Optimal concentrations of each component of the stimulatorycompositions, culture conditions and duration can be determinedempirically using routine experimentation.

Populations of TFR cells expanded/activated in the presence of a PD-1 orPD-1 ligand antagonist have enhanced suppressive activity asdemonstrated by their ability to inhibit TFH-mediated antibodyproduction in vitro and in vivo as demonstrated in appropriate assays asare described herein.

Populations TFH cells expanded/activated in the presence of a PD-1 orPD-1 ligand antagonist have enhanced antibody stimulatory activity asdemonstrated by their ability to enhance TFH-mediated antibodyproduction in vitro and in vivo as demonstrated in appropriate assaysdescribed herein. Such TFH cells are referred to herein as “TFH cellshaving enhanced stimulatory capacity”.

IV. Modulation of the Immune System

The expanded and/or activated TFR cells and compositions thereof asdescribed herein may be introduced into the subject to treat immunerelated diseases, for example, by modulating an autoimmune reaction. Forexample, the subject may be afflicted with a disease or disordercharacterized by having an ongoing or recurring autoimmune reaction,such as the diseases/disorders including, but not limited to, lupuserythematosus; myasthenia gravis; autoimmune hepatitis; rheumatoidarthritis; multiple sclerosis; Grave's disease, and graft versus hostdisease (GVHD).

In one embodiment, if upregulation of an immune response in a subject isdesired, such as for example, increasing antibody amount or quality inresponse to a vaccine, an enriched and optionally expanded and/oractivated composition comprising a starting population of TFH cells maybe administered to a subject.

In one embodiment modulation of the immune system is achieved when uponadministration of a composition of the invention, the ratio of TFR cellsto TFH cells in a subject is changed as compared to the ratio of TFRcells to TFH cells in a subject prior to administration of a compositionof the invention. The ratios of TFR cells to TFH cells in a subjectprior to, and after, administration of a composition of the inventionmay be measured by assaying for the presence of TFR cells or TFH cellsin a patient's blood. Examples of suitable assays for measuring theratio of TFR cells to TFH cells in a patient's blood are describedherein.

In one embodiment, if downregulation of a subject's immune response isdesired, such as, for example, when the subject has an autoimmunedisease and inhibition of an antibody response is desired, a highlypurified composition of blood derived TFR cells, or a compositionenriched for TFR cells having enhanced suppressive activity may beadministered to a patient. After administration of the composition, ablood sample from the patient may be tested to determine if the ratio ofTFR cells to TFH cells is high.

In one embodiment, if upregulation of an immune response in a subject isdesired, such as for example, increasing antibody proliferation inresponse to a vaccine, a highly purified composition of blood-derivedTFH cells may be administered to a patient. After administration of TFHcomposition, a blood sample from the patient may be tested to determineif the ratio of TFH cells to TFR cells is high.

Accordingly, the invention provides methods and compositions foradoptive cellular immunotherapy comprising introducing into a patient inneed thereof an effective amount of the subject's ex vivoexpanded/activated TFR cells, for example. These applications generallyinvolve reintroducing expanded/activated TFR cells extracted from thesame patient, though the methods are also applicable to adoptivecellular immunotherapy for treatment of graft-versus-host diseaseassociated with transplantation, particularly bone marrowtransplantation using TFRs derived from donor tissue, and/or healthyindividuals.

In an exemplary adoptive cell transfer protocol comprises a mixedpopulation of cells is initially extracted from a target donor.Depending on the application, the cells may be extracted during a periodof remission, or during active disease. Typically this is done bywithdrawing whole blood and harvesting PMBCs by, for example,leukapheresis (leukopheresis). For example, large volume leukopherisis(LVL) has been shown to maximize blood leukocyte yield. Harvests reach20×106 cells/L using a continuous flow apheresis device (Spectra, COBEBCT). Symptoms of hypocalcemia are avoided by a continuous infusion ofcalcium administrated throughout leukopheresis. Typically 15-45 litersof fluid corresponding to about 4 total blood volumes are harvestedduring a period of time ranging from about 100 to 300 minutes.

The harvested PMBCs may be separated by flow cytometry or other cellseparation techniques based on Treg and/or TFR-specific cell markerssuch as CD4, CD25, CXCR5, ICOS, and GITR and expanded/activated asdescribed herein, and then transfused to a patient, preferably by theintravenous route, typically the cell donor (except in GVHD where thedonor and recipient are different), for adoptive immune suppression.Alternatively, the cells may be frozen for storage and/or transportprior to and/or subsequent to expansion.

Effective and optimized dosages and treatment regimens using theexpanded and/or enriched and optionally highly pure TFH or TFR cells areknown in the art based on previous clinical experience with existingT-cell infusion therapies, and can be further determined empirically.

The preferred route of administration of the TFR and TFH cellcompositions to a subject in accordance with the invention is by theintravenous route. However, depending on the application, cellcompositions in accordance with the invention may be administered byother routes including, but not limited to, parenteral, oral or byinhalation.

V. Vaccination

The present invention also contemplates a method for enhancing an immuneresponse to an antigen comprising the administration to a subject aspart of a vaccination regimen, TFR cells having enhanced suppressiveactivity, TFR cell compositions derived from peripheral blood, TFH cellshaving enhanced stimulation activity, or TFH cells derived fromperipheral blood. The present invention is particularly useful inpharmaceutical vaccines and genetic vaccines in humans

Adjuvants promote the immune response in a number of ways such as tomodify the activities of immune cells that are involved with generatingand maintaining the immune response. Additionally, adjuvants modify thepresentation of antigen to the immune system. The compositions of theinvention may be used as adjuvants in a vaccination regimen.

In one embodiment, compositions of TFH or TFR cells in accordance withthe invention may be used in a vaccination regimen. Without beinglimited to a specific theory, it is believed that TFR cells inhibit GC Bcells, resulting in reduced class switch recombination and antibodyproduction and TFH cells stimulate GC B cells and antibody production.

In one embodiment compositions of TFH cells, particularly TFH cellsderived from the peripheral blood of a patient (also referred to hereinas “blood TFH cells”) may be used in a vaccination regimen to enhanceTFH cell mediated antibody responses. Without being limited to anyparticular theory, it is believed that TFH cells derived from the bloodmigrate to lymph nodes and interact with cognate B cells rapidly uponantigen exposure, wherein naïve T cells need at least two to four daysto differentiate and upregulate CXCR5. Accordingly, TFH cells derivedfrom blood have greater antibody stimulatory capacity.

In one embodiment, it may be desirable to upregulate an immune responseor downregulate an immune response as part of a vaccination regimen.This can be accomplished by administering compositions enriched for orhighly purified for TFR cells or compositions enriched for or highlypurified TFH cells to change the ratio of TFR cells to TFH cells in asubject's blood in combination with the administration of a vaccine.

In some embodiments, the vaccine may comprise a composition of TFH cellsand a cytokine (e.g., IL-21 or IL-6) or metabolic modulator.

The present invention also contemplates a method for enhancing an immuneresponse to an antigen comprising the administration to a subject aspart of a vaccination regimen a cytokine (e.g., IL-21 or IL-6) ormetabolic modulator. Administering an antigen and/or adjuvant to asubject in combination with IL-21, IL-6 or metabolic modulators mayinhibit the activity of the subjects TFR cells resulting in a similareffect as TFH/TFR compositions

Exemplary metabolic modulators include but are not limited to2-deoxyglucose, metformin, methotrexate, azathioprine, rapamycin,dichloroacetate, lonidamine, alpha-tocopheryl succinate, methyljasmonate, betulinic acid, and resveratrol.

VI. Novel In-Vivo and In Vitro Assays

The invention also provides in vivo and in vitro assays to analyze thefunctions of the compositions of TFR cells and TFH cells in accordancewith the invention.

In one exemplary embodiment the invention provides an assay to analyzethe capacity of TFR cells to inhibit activation of CD4 T cellpopulations such as TFH cells. Briefly, WT and PD-1−/− mice areimmunized with MOG/CFA and TFR cells are sorted from draining lymphnodes and plated 1:1:1 with CFSE-labeled CD4 naïve WT (CD4+CD62L+FoxP3−)responder cells and WT GL7-B220+B cells from MOG/CFA immunized micealong with anti-CD3 and anti-IgM for 4 days. 3 days later samples areanalyzed by flow cytometry. It is understood that any suitableantigen/adjuvant combinations may be used to immunize mice and that thecells may be stimulated by any suitable combinations of stimulatoryfactors for this assay.

In one exemplary embodiment the invention provides an assay to analyzecapacity of TFR cells to inhibit activation of naïve CD4 T cells. WT andPD-1−/− mice are immunized with MOG/CFA and TFR cells and sorted fromdraining lymph nodes and plated 1:1:1 with CFSE-labeled CD4 naïve WT(CD4+CD62L+FoxP3−) responder cells and WT GL7-B220+B cells from MOG/CFAimmunized mice along with anti-CD3 and anti-IgM for 4 days. 3 days latersamples are analyzed by flow cytometry. T responders are analyzed forCD69 expression and proliferation by measuring CFSE dilution.

In one embodiment the invention provides an assay for an in vitro IgGsuppression. Briefly, TFR cells are sorted as in the assay to analyzecapacity of TFR cells to inhibit activation of naïve CD4 T cells and areplated in a 1:1:1 ratio of TFR (CD4+ICOS+CXCR5+GITR+CD19−), TFH(CD4+ICOS+CXCR5+GITR−CD19−), and B (GL-7-B220+) cells from draininglymph nodes of MOG/CFA immunized mice in the presence of anti-CD3 andanti-IgM for 6 days. Total IgG was measured by ELISA from supernatants.In one embodiment the in-vitro suppression assay may be performed over arange of concentrations of anti-CD3. Naive (CD4+ICOS−CXCR5−CD19−) cellsfrom immunized mice may be included as controls It is understood thatany suitable antigen/adjuvant combinations may be used to immunize miceand that the cells may be stimulated by any suitable combinations ofstimulatory factors for this assay.

Novel assays of the invention are useful as a diagnostic tool formeasuring a subject's TFR cell function and TFH cell function. Suchassays are useful in the identification and typing of autoimmunediseases.

The assays of the invention are also useful in measuring the ratio ofTFR cells to TFH cells in a patient's blood prior to or during an immuneresponse and/or prior to and after administration of a composition ofthe invention. Such assays are useful as a diagnostic to assist indetermining whether an immune response in a subject should beupregulated or down-regulated or whether an immune modulating treatmentregimen has had the desired effect. This assay also may be useful in thediagnosis or progression of specific diseases.

In accordance with the invention, an exemplary assay comprises a methodfor assaying the TFR cell function or the TFH cell function or both, ina patient comprising the steps of:

a) Obtaining a sample of peripheral blood from a patient;

b) Isolating a population of TFH cells and TFR cells from the bloodsample;

c) Contacting the TFH cells and TFR cells with a stimulatory compositioncomprising antigen present cells (e.g. B cells) in the presence ofT-cell receptor stimulating factors and cofactors such as anti-CD3 andanti-IgM, for a time period sufficient to allow the production ofantibody such as IgG; and

-   -   d) measuring the total antibody produced using standard assays        (e.g. ELISA).

VII. Modulation of TFR and TFH Cell-Mediated Immune Responses ViaSelective TFR and TFH Cell Surface Receptors

The data in FIG. 23 of PCT/US2013/069197, hereby incorporated byreference, shows that TFR cells are distinct in their gene expression ascompared to Treg cells and TFH cells suggesting that TFR cells arecapable of independently regulating immune responses. This knowledge maybe applied to diagnose, monitor and treat diseases or conditions whereinTFR-immune responses may be selectively modulated such as in thosediseases or conditions in which antibodies play a key role in thepathogenesis and enhanced immune suppression is therapeutic. Examples ofsuch diseases are provided herein supra.

TFR cell function may be modulated by use of an agent such as an agonistor an antagonist of one or more of TFR cell surface receptors asdescribed herein. Use of such an agent in an amount effective to inhibitor induce the differentiation of TFR cells and/or modulate thebiological function of TFR cells can affect the TFR cell-mediated immuneresponse.

In one embodiment, the invention provides a method suppressing apathogenic antibody response in a patient in need thereof comprising,administering to the patient, an agent which modulates at least onereceptor which is differentially expressed on TFR cells as compared toTFH cells at an increased mean fluorescence intensity (MFI) fold changeof at least 1.17, and wherein the receptor has an MFI of at least 186 onTFR cells and wherein the agent administered in an amount that iseffective to modulate the TFR receptor and increase TFR cell-mediatedantibody suppression, as compared to the TFR cell-mediated antibodysuppression in the absence of the agent. Such differentially expressedreceptors are referred to herein as “selective TFR receptors”. In oneembodiment at least one selective TFR receptor is selected from one ormore of: CD162, CD27, CD95, CD9, CD43, CD278 (ICOS), CD50, CD45RB,CD102, CD61, CD58, CD196, CD38, CD31, CD15, CD25, CD13, CD66a/c/e, CD11bCD63, CD32, CD97, HLA-HQ, CD150, Siglec-9, Integrinβ7, CD71, CD180,CD218a, CD193, CD235ab, CD35, CD140a, CD158b, CD33, CD210, HLA-G,CD167a, CD119, CX3CR1, CD146, HLA-DR, CD85, CD172b, SSEA-1, CD49c,CD170, CD66b, and CD86. In one embodiment, selective TFR receptors areselected from one or more of: CD27, CD278 (ICOS), CD150, Siglec-9,CD140a, CD158b, and CD33.

Methods of modulating TFR cell-mediated immune response throughantagonizing or agonizing the biological function of a selective TFRreceptor are useful in the treatment of diseases and conditions whereina decreased or increased TFR cell-mediated immune response is useful.Examples of disorders or conditions which may be treated by increasingTFR cell-mediated immune response include those diseases and conditionsin which antibodies contribute to and/or are primarily responsible for,pathogenesis such as in those diseases listed previously herein. In oneembodiment the disease or condition in which antibodies contributeand/or are primarily responsible for pathogenesis include: multiplesclerosis, systemic lupus erythematosus, allergy, myasthenia gravis,collagen diseases, glomerulonephritis, Devic's disease, vasculitiscaused by ANCA, and celiac disease.

In one embodiment, the agent is a blocking antibody capable ofblocking/antagonizing a selective TFR receptor, or binding to the ligandof the receptor and thereby blocking its ability to bind itscorresponding receptor. The agent may also be a small molecule, or a DNAor RNA molecule (e.g. dsRNA, or antisense molecule) capable ofantagonizing or agonizing the biological function of the receptor, forexample by causing overexpression of a receptor or by blockingexpression of a receptor.

In addition to the known agonists and antagonists of various selectiveTFR receptors known generally, other agents may be tested for theirability to antagonize or agonize selective TFR receptors using knownassays and screens.

Assays and screens of the invention useful for testing various agentsfor their ability to agonize or antagonize TFR cell surface receptorsare used to identify agents of the invention. In one embodiment, theinvention provides assays to specifically and sensitively determine thestimulatory function of TFH cells. Complementary assays are alsoprovided which determine the inhibitory capacity of TFR cells. Theseassays which include both in vitro and in vivo experiments can be usedto determine the functional consequences of sending agonist and/orantagonist signals through surface receptors on TFH and TFR cells.

In vitro murine TFH stimulation assays are performed byimmunizing/vaccinating mice with an antigen/adjuvant. In some cases liveor attenuated virus can be used. Seven to ten days later TFH cellsdefined as (CD4+ICOS+CXCR5+FoxP3+CD19−) or (CD4+ICOS+CXCR5+GITR+CD19−)(or alternative TFH marker) are sorted by flow cytometry. TFH cells areincubated with B cells along with anti-CD3 and anti-IgM (oralternatively with specific antigen).

Agonists and/or antagonists for TFH surface receptors are also addedinto cultures. After 7 days antibody production and class switchrecombination is assessed by either staining B cells from the culturefor activation markers (B7-1, GL7, etc.) or intracellular for IgGisotypes. Activation status of the TFH cell can also be determined.

Alternatively, the supernatants can be assessed for presence of IgGs viaELISA. Examples of this assay are included in FIGS. 4, 20 and 21 ofPCT/US2013/069197, hereby incorporated by reference. Similar assays areperformed using human cells isolated from blood or other tissues.

In vivo murine TFH stimulation assays are performed byimmunizing/vaccinating mice with an antigen/adjuvant. In some cases liveor attenuated virus can be used.

Seven to ten days later TFH cells defined as(CD4+ICOS+CXCR5+FoxP3−CD19−) or (CD4+ICOS+CXCR5+GITR−CD19−) (oralternative TFH marker) are sorted by flow cytometry. Cells are eitherused right away, or incubated in vitro with agonists or antagonists asin in vitro assays. Cells are adoptively transferred intravenously tomice that are vaccinated or likewise challenged with antigen and/orvirus. Ten days later serum is collected from mice and IgGs are detectedby ELISA. Within these 10 days agonists or antagonists for TFH surfacereceptors can be administered.

Examples of this assay are in FIGS. 8 and 21 of PCT/US2013/069197,hereby incorporated by reference. These assays can also be used todetermine how TFH cells change disease autoimmune pathology. As anexample, mice can be immunized with collagen and then TFH cells can besorted and transferred to a new mouse that is immunized with collagen.The resulting anti-collagen antibodies will cause arthritis which can bemeasured to determine how TFH cells function within this specificdisease. Additionally, these assays can be used to determine TFHstimulation of B cell antibody production in the context of vaccinationby using TFH cells from influenza infected mice and then adoptivelytransfer them to a new mouse that is infected with influenza. Extent ofviral infection can be measured as a readout for antibody mediatedclearance of virus.

In vitro murine TFR suppression assays are performed byimmunizing/vaccinating mice with an antigen/adjuvant. In some cases liveor attenuated virus can be used. Seven to ten days later TFH cellsdefined as (CD4+ICOS+CXCR5+FoxP3−CD19−) or (CD4+ICOS+CXCR5+GITR−CD19−)(or alternative TFH marker) and TFR cells defined as(CD4+ICOS+CXCR5+FoxP3+CD19−) or (CD4+ICOS+CXCR5+GITR+CD19−) (oralternative TFR marker) are sorted by flow cytometry. TFH and/or TFRcells are incubated with B cells along with anti-CD3 and anti-IgM (oralternatively with specific antigen). Agonists and/or antagonists forTFR surface receptors are also added into cultures. After 7 daysantibody production and class switch recombination is assessed by eitherstaining B cells from the culture for activation markers (B7-1, GL7,etc.) or intracellular for IgG isotypes. Activation status of the TFHcell can also be determined. Alternatively, the supernatants can beassessed for presence of IgGs via ELISA. Examples of this assay areincluded in FIGS. 4, 20 and 21 of PCT/US2013/069197, hereby incorporatedby reference. Similar assays are performed using human cells isolatedfrom blood or other tissues.

In vivo murine TFR suppression assays are performed byimmunizing/vaccinating mice with an antigen/adjuvant. In some cases liveor attenuated virus can be used. Seven to ten days later TFH cellsdefined as (CD4+ICOS+CXCR5+FoxP3+CD19−) or (CD4+ICOS+CXCR5+GITR+CD19−)(or alternative TFH marker) and TFR cells defined as(CD4+ICOS+CXCR5+FoxP3+CD19−) or (CD4+ICOS+CXCR5+GITR+CD19−) (oralternative TFR marker) are sorted by flow cytometry. Cells are eitherused right away, or incubated in vitro with agonists or antagonists asin in vitro assays. Cells are adoptively transferred intravenously tomice that are vaccinated or likewise challenged with antigen and/orvirus. Ten days later serum is collected from mice and IgGs are detectedby ELISA. Within these ten days agonists or antagonists for TFR surfacereceptors can be administered. These assays can also be used todetermine how TFR cells change disease pathology. As an example, micecan be immunized with collagen and then TFH and TFR cells can be sortedand transferred to a new mouse that is immunized with collagen. Theresulting anti-collagen antibodies will cause arthritis which can bemeasured to determine how TFR cells function to suppress the TFHmediated disease.

The present invention further provides agents identified in the assaysdescribed herein. Such agents are capable of up antagonizing oragonizing a selected TFR receptor and thereby modulate TFR cell-mediatedimmune function and to further treat diseases as described herein.

Animal model systems which can be used to screen the effectiveness ofthe selected agents and test agents of the present invention inprotecting against or treating the disease are available. Methods forthe testing of systemic lupus erythematosus (SLE) in susceptible miceare known in the art (Knight et al. (1978) J. Exp. Med., 147: 1653;Reinersten et al. (1978) New Eng. J. Med., 299: 515). Myasthenia Gravis(MG) is tested in SJL/J female mice by inducing the disease with solubleAchR protein from another species (Lindstrom et al. (1988) Adv.Immunol., 42: 233). Arthritis is induced in a susceptible strain of miceby injection of Type II collagen (Stuart et al. (1984) Ann. Rev.Immunol., 42: 233). A model by which adjuvant arthritis is induced insusceptible rats by injection of mycobacterial heat shock protein hasbeen described (Van Eden et al. (1988) Nature, 331: 171). Thyroiditis isinduced in mice by administration of thyroglobulin as described (Maronet al. (1980) J. Exp. Med., 152: 1115). Insulin dependent diabetesmellitus (IDDM) occurs naturally or can be induced in certain strains ofmice such as those described by Kanasawa et al. (1984) Diabetologia, 27:113. EAE in mouse and rat serves as a model for MS in human. In thismodel, the demyelinating disease is induced by administration of myelinbasic protein (see Paterson (1986) Textbook of Immunopathology, Mischeret al., eds., Grune and Stratton, New York, pp. 179-213; McFarlin et al.(1973) Science, 179: 478: and Satoh et al. (1987) J. hnmunol., 138:179).

Generally, suitable agents identified and tested as described above willbe used in purified form together with pharmacologically appropriatecarriers. Typically, these carriers include aqueous or alcoholic/aqueoussolutions, emulsions or suspensions, any including saline and/orbuffered media. Parenteral vehicles include sodium chloride solution,Ringer's dextrose, dextrose and sodium chloride and lactated Ringer's.Suitable physiologically-acceptable adjuvants, if necessary to keep, forexample, a polypeptide complex such as an antibody in suspension, may bechosen from thickeners such as carboxymethylcellulose,polyvinylpyrrolidone, gelatin and alginates. Intravenous vehiclesinclude fluid and nutrient replenishers and electrolyte replenishers,such as those based on Ringer's dextrose. Preservatives and otheradditives, such as antimicrobials, antioxidants, chelating agents andinert gases, may also be present (Mack (1982) Remington's PharmaceuticalSciences, 16th Edition).

The selected agents of the present invention may be used as separatelyadministered compositions or in conjunction with other agents. These caninclude various immunotherapeutic drugs, such as cylcosporine,methotrexate, adriamycin or cisplatinum, and immunotoxins.Pharmaceutical compositions can include “cocktails” of various cytotoxicor other agents in conjunction with the agents of the present invention.

The route of administration of pharmaceutical compositions according tothe invention may be any of those commonly known to those of ordinaryskill in the art. For therapy, including without limitationimmunotherapy, the selected agents can be administered to any patient inaccordance with standard techniques. The administration can be by anyappropriate mode, including parenterally, intravenously,intramuscularly, intraperitoneally, transdermally, via the pulmonaryroute, or also, appropriately, by direct infusion with a catheter. Thedosage and frequency of administration will depend on the age, sex andcondition of the patient, concurrent administration of other drugs,counterindications and other parameters to be taken into account by theclinician.

In certain therapeutic applications, an adequate amount to accomplishmodulation of a TFR and/or TFH cell-mediated immune response will dependupon the severity of the disease and the general state of the patient'sown immune system. Generally, if the agent is a blocking antibody, forexample, a range from 0.01 mg-100 mg per kilogram of body weight, withdoses of 1-10 mg/kg would be suitable.

A composition containing one or more selected agents according to thepresent invention may be used in prophylactic and therapeutic settingsto aid in the modulation of a TFR and/or TFH cell-mediated response. Inaddition, the agents described herein may be used extracorporeally or invitro to selectively modulate TFR and/or TFH cell-mediated immuneresponses.

The invention also provides agents and methods for modulating TFHcell-mediated immune responses. TFH cells are known in the prior art tobe a subset of T helper cells that are genetically distinct from othertypes of T helper cells suggesting that TFH cells contribute to immuneresponses. This knowledge may be applied to diagnose, monitor and treat,for example, diseases or conditions wherein enhancement of a protectiveantibody response is therapeutic. Such diseases include but are notlimited to treating viral infections and treating cancer. Enhancing andpreferably selectively enhancing, TFH cell-mediated immune responses arealso particularly beneficial as part of a vaccine or vaccinationregimen.

TFH cell function may be modulated by use of an agent such as an agonistor an antagonist of one or more of TFH cell surface receptors asdescribed herein. Use of such an agent in an amount effective to inhibitor induce the differentiation of TFH cells and/or modulate thebiological function of TFH cells can affect the TFH cell-mediated immuneresponse.

In one embodiment, the invention provides method of increasing aprotective antibody response in a patient in need thereof comprisingadministering to the patient, an agent which modulates at least onereceptor which is differentially expressed on TFH cells as compared toTFR cells at an increased mean fluorescence intensity (MFI) fold changeof at least 1.17, and wherein the receptor has an MFI of at least 200 onTFH cells and wherein the agent is effective to modulate the receptorand increase the antibody response in the patient as compared to theantibody response when the agent is absent. Such differentiallyexpressed receptors are referred to herein as “selective TFH receptors”.In one embodiment at least one selective TFH receptor is selected fromone or more of: CD163, CD127, CD8a, CD89, CD197, CD161, CD6, CD229,CD96, CD272, CD148, CD107a, CD100, CD82, CD126, CD45RO, PD-1 (CD279),CD5, and CD99. In one embodiment, at least one selective TFH receptor isselected from one or more of: CD163, CD127, CD161, CD6, CD229, CD272,CD100, CD126, PD-1 (CD279).

In one embodiment, the agent is a blocking/antagonizing antibody capableof blocking a selective TFH receptor, or binding to the ligand of thereceptor and thereby blocking its ability to bind its correspondingreceptor. The agent may also be a small molecule, or a DNA or RNAmolecule (e.g. dsRNA, or antisense molecule) capable of antagonizing oragonizing the receptor.

In addition to the known agonists and antagonists the various selectiveTFH receptors described herein, other agents may be tested for theirability to antagonize or agonize selective TFH receptors using knownassays and screens. Assays and screens for testing various agents fortheir ability to agonize or antagonize TFH cell surface receptors aredescribed previously herein. Animal models may be used to testmodulation of selective TFH receptors as described previously herein.

The present invention further provides agents identified in the assaysdescribed herein wherein such agents are capable of antagonizing oragonizing a selective TFH receptor and thereby modulate TFHcell-mediated immune function. Agents for modulating selective TFHreceptors may be formulated and administered to patients as describedabove.

In one embodiment, the invention provides a method of decreasing apathogenic antibody response in a patient in need thereof comprisingadministering to the patient a first agent capable of modulating aselective TFR receptor in an amount effective to increase TFRcell-mediated antibody suppression in the patient, alone or incombination with an second agent capable of modulating a selective TFHreceptor in an amount effective to decrease TFH cell-mediated antibodyproduction, wherein the pathogenic antibody response is decreased ascompared to the pathogenic antibody response in the absence of the firstor second agents.

In one embodiment, the invention provides a method of increasing aprotective antibody response in a patient in need thereof comprisingadministering to the patient a first agent capable of modulating aselective TFR receptor in an amount effective to decrease TFRcell-mediated antibody suppression in the patient, alone or incombination with a second agent capable of modulating a selective TFHreceptor in an amount effective to increase TFH cell-mediated antibodyproduction, wherein the protective antibody response is increased ascompared to the protective antibody response in the absence of the firstor second agents.

VIII. Modulation of TFR and TFH Cell-Mediated Immune Responses Via PD-1Receptors

The inventors' discovery that PD-1:PD-L1 interactions limit TFR celldifferentiation and function has also elucidated another novel approachto modulating both TFR cell-mediated and TFH cell-mediated immuneresponses in a patient.

Therefore, in one embodiment the invention provides a method ofdecreasing a pathogenic antibody response in a patient in need thereofcomprising administering to the patient, an agent which modulates thePD-1 receptor on a TFR cell. In one embodiment, the agent is anantagonist of the PD-1 receptor on a TFR cell. In one embodiment, theagent is an antibody capable of blocking the PD-1 receptor on a TFRcell. In one embodiment, the agent is an antibody capable of binding toa ligand selected from PD-L1 or PD-L2 and preventing the ligand frombinding to the PD-1 receptor. The agent may also be a small molecule, ora DNA or RNA molecule (e.g., dsRNA, or antisense molecule) capable ofantagonizing or agonizing the receptor.

In one embodiment a disease or condition wherein suppression of apathogenic antibody response is therapeutic includes those diseaseslisted previously in which antibodies contribute to, or are primarilyresponsible for pathogenesis.

In another embodiment, the invention provides a method of increasing aprotective antibody response in a patient in need thereof comprisingadministering to the patient, an agent which modulates the PD-1 receptoron a TFH cell. In one embodiment the agent is an agonist of the PD-1receptor on a TFH cell. The agent may also be a small molecule, or a DNAor RNA molecule (e.g. dsRNA, or antisense molecule) capable of agonizingthe PD-1 receptor.

In one embodiment, the invention provides a method of decreasing apathogenic antibody response in a patient in need thereof comprisingadministering to the patient a first agent capable of modulating a PD-1receptor on a TFR cell in an amount effective to increase TFRcell-mediated antibody suppression in the patient, in combination withan second agent capable of modulating a PD-1 receptor on a TFH cell inan amount effective to decrease TFH cell-mediated antibody production,wherein the pathogenic antibody response is decreased as compared to thepathogenic antibody response in the absence of the first or secondagents.

In one embodiment, the invention provides a method of increasing aprotective antibody response in a patient in need thereof comprisingadministering to the patient a first agent capable of modulating a PD-1receptor on a TFR cell in an amount effective to decrease TFRcell-mediated antibody suppression in the patient, in combination with asecond agent capable of modulating a PD-1 receptor on a TFH receptor inan amount effective to increase TFH cell-mediated antibody production,wherein the protective antibody response is increased as compared to theprotective antibody response in the absence of the first or secondagents.

In addition to the known agonists and antagonists of the PD1 receptorgenerally, other agents may be tested for their ability to antagonize oragonize PD-1 on TFH and TFR cells using known assays and screens. Assaysand screens for testing various agents for their ability to agonize orantagonize PD-1 receptors are previously described. Animal models may beused to test modulation of selective TFH receptors as described above.

The present invention further provides agents identified in the assaysdescribed herein wherein such agents are capable of antagonizing oragonizing PD-1 receptors and thereby modulate TFR or TFH cell-mediatedimmune function or both.

Agents for modulating PD-1 receptors on TFR or TFH cells may beformulated and administered to patients as described above.

The following examples are intended to promote a further understandingof the disclosure. While the disclosure is described herein, withreference to illustrated embodiments, it should be understood that thedisclosure is not limited hereto. Those having ordinary skill in the artand access to the teachings herein will recognize additionalmodifications and embodiments within the scope thereof. Therefore, thedisclosure is limited only by the claims attached herein.

EXAMPLES

Aspects and exemplifications relating to the 1) PD-1 Controls TFollicular Regulatory Cells; 2) PD-1 Deficient TFR cells are Capable ofHoming to Germinal Center; 3) PD-1 deficient TFR cells More PotentlyInhibit T Cell Activation; 4) PD-1 Controls Blood T FollicularRegulatory Cells; 5) Blood TFH and TFR cells require CD28 and ICOSSignals; 6) PD-1 deficient blood TFR cells more potently regulateantibody production in vivo; 7) T Follicular Regulatory cell (TFR)Cellular Therapy Strategies; 8) Differentiation of Circulating TFH andTFR cells Require Priming by Dendritic Cells; 9) Blood TFH and TFR CellsExit the Lymph Node via SIP Signals; 10) Circulating TFH and TFR cellsMigrate to Diverse Lymph Nodes and Tissues; 11) Circulating TFH and TFRcells are More Potently Activated After Transfer in vivo; 12)Circulating TFH cells Require Dendritic Cells for Restimulation and HaveMemory Properties; 13) TFR cells Potently Suppress T Cell and B CellActivation; 14) Weaker B cell Suppression by Blood TFR cells; 15)Comparison of TFR and Treg gene expression signatures; 16) Surfacereceptors differentially expressed by human blood TFR cells; 17) Surfacereceptors differentially expressed by human blood TFH cells; and 18)Blockade of the PD-1 pathway can heighten antibody stimulating capacityof TFH cells are provided in Ser. No. 14/707,596, PCT/US2013/069197,filed Nov. 8, 2013, and U.S. provisional application No. 61/724,424,filed Nov. 9, 2012, and are hereby incorporated by reference in thereentirety.

Example 1—B Cells Suppressed by TFR Cells Undergo Early Activation

To determine the mechanisms of how TFH and B cells are altered duringdirect TFR suppression, an in vitro suppression assay in which TFR cellsare cultured with TFH and B cells was utilized. See e.g., Sage et al., JClin Invest 124, 5191-5204 (2014); Sage et al., Immunity 41, 1026-1039(2014); Sage et al., Methods Mol Biol 1291, 151-160 (2015). For theseassays, FoxP3IRES-GFP mice were immunized with NP-OVA (emulsified inCFA) subcutaneously and isolated draining lymph nodes 7 days later. TFR(sorted as CD4+ICOS+CXCR5+CD19−FoxP3+) cells were added to co-culturesof B (sorted as CD19+) and TFH (sorted as CD4+ICOS+CXCR5+CD19−FoxP3)cells along with anti-CD3 and anti-IgM for 2 to 6 days (FIG. 1A, FIG.36A, and FIG. 36B). After 6 days of co-culture of B and TFH cells,robust upregulation of the GC B cell marker GL7 was found as well asclass switch recombination to IgG1, the predominant class switchedisotype in this model (FIG. 1B). In addition, robust quantities ofsecreted IgG were found in the culture supernatant when B cells werecultured with TFH cells, but not when B cells were cultured alone.However when TFR cells were added to B and TFH cultures, class switchrecombination, GL7 expression and secretion of antibody was severelydiminished, demonstrating that TFR cells potently suppress B celleffector functions. CD4⁺CXCR5⁻ICOS⁻Foxp3⁺ Treg cells were not able tosuppress as efficiently as TFR cells did (FIG. 15). TFR cells alsosuppressed CSR of B cells in response to specific antigen (FIG. 36C).Furthermore, the suppression of CSR by TFR cells required cell contact,as supernatant from TFR cultures did not suppress B cells (FIG. 16).Time-lapse microscopy of cultures revealed that TFR cells closelyinteracted with both TFH cells and B cells (FIG. 17). These datasuggested that TFR cells might physically disrupt TFH cell- and Bcell-linked recognition during suppression. Therefore, this culturesystem is a robust model to study TFR suppression of TFH and B cells.

Next, it was determined whether TFR suppression of B cells results in atotal lack of B cell activation, or if suppression is more targeted todownstream effector functions. Similar in vitro suppression assays wereperformed except B cells were labeled with a cell trace violet (CTV)proliferation dye. When B cell proliferation (by assessing CTV dilution)was analyzed after co-culture with or without TFR cells, it was foundthat despite a decrease the numbers of cell divisions, the vast majorityof B cells had proliferated at least one cell cycle when TFR cells werepresent (FIG. 1C). Therefore, TFR cells suppression does not completelyprevent proliferation of B cells in co-cultures of only TFR cells and Bcells (without TFH cells) and lipopolysaccharide plus IL-4 (FIG. 18). Todetermine if early activation of B cells was affected by TFR cells, CD69expression on B cells during the first few days of co-culture wasanalyzed. Surprisingly, CD69 was upregulated in B cells whether or notsuppressive TFR cells were present within the first three days ofculture, demonstrating that early activation of B cells still occursduring TFR cell suppression (FIG. 1D). Therefore, although TFR cellsinhibit proliferation and effector functions of B cells, the suppressedB cells show evidence of some activation and proliferation.

One possible explanation for defective effector functions of B cellsduring TFR suppression is that TFR cells may be inducing cell death in Bcells. Therefore, cell death was assessed through staining B cells withthe active caspase reagent, zVAD. In these co-culture experiments TFHcells induce cell death in B cells which is consistent with high amountsof cell death within germinal centers during affinity maturation in vivo(FIG. 1E). However, when TFR cells were present, cell death wasdramatically decreased in B cells which suggests that TFR cells do notalter B cell responses through sensitizing B cells to undergo apoptosis.Affinity maturation of B cells in GCs occurs through a balance betweensomatic hypermutation and cell death. To determine if TFR cells canalter somatic hypermutation, in vitro suppression assays were performedand added specific antigen (NP-OVA) (instead of anti-CD3 and anti-IgM)to facilitate the testing of mutated B cell receptors in culture. Bcells were sorted after 6 days of culture and sequenced the B cellreceptor heavy chain and analyzed somatic hypermutation. A moderatelylow frequency of mutations per unique VDJ sequence in cultures of Bcells with TFH cells was found (FIG. 1F). TFR cells (but not Treg cells)also suppressed the activation of TFH cells, as indicated by reducedexpression of Bc16 and the proliferation marker Ki67 (FIG. 19). However,when TFR cells were added, fewer mutations per unique VDJ sequence werefound which demonstrates that TFR cells can suppress somatichypermutation of B cells. Taken together, these data demonstrate the invitro suppression assay robustly measures TFR suppression of B cells andthat this suppression allows B cells to receive some activation signals.

Example 2—Suppressed B and TFH Cells Downregulate a Small Subset ofEffector Genes but Still Resemble Effector Cells

These findings suggested that TFR cells suppress B cells in a way thatallows the B cell to receive some activation signals, yet is unable toperform effector functions such as class switch recombination, somatichypermutation or antibody secretion. In order to determine how B and TFHcells effector states are altered during TFR mediated suppression assayswere performed followed by RNA-seq transcriptome analysis. In theseexperiments B and TFH cells (from immunized FoxP3-IRES-GFP mice) werecultured with or without TFR cells (from immunized ActinCFPFoxP3-IRES-GFP mice) for 6 days in the presence of NP-OVA (the sameantigen used to generate the B, TFH and TFR cells). After 4 days ofculture, B (sorted as CD19+IA+CD4−) and TFH (sorted as CD4+IA−CD19−CFP−)cells were sorted from the “activated” culture (TFH and B cells alone)or from the “suppressed” culture (TFH, B and TFR cells) and RNAseqtranscriptional analysis was performed (FIG. 2A, FIG. 37A and FIG. 37B).

By principle component analysis (PCA), slight separation of activatedand suppressed B cells was found, but not activated or suppressed TFHcells (FIG. 2B). TFH and B cell populations separated as expected sincethese are distinct lineage cells. 1171 genes were found that weredifferentially expressed (FDR adjusted p value<0.05) between activatedand suppressed B cells, but only 407 genes that were differentiallyexpressed between activated and suppressed TFH cells (FIG. 2C, and FIG.37C—FIG. 37F). Therefore, TFR suppression elicits more transcriptionalchanges in B cells than in TFH cells.

Next, whether TFR suppression affects TFH cell identity and function wasdetermined. To do this, a list of TFH genes that regulate TFH celldifferentiation/function was compiled and differences between activatedor suppressed TFH cells were analyzed. Surprisingly, no downregulationof TFH transcription factors such as Bc16 or Asc12 associated withsuppression was found (FIG. 2E). However, both IL-4 and IL-21transcripts were potently downregulated in TFH cells during TFRsuppression. This data suggests that after TFR mediated suppression, TFHcells still retain their TFH program, but have downregulation of keyeffector molecules. To confirm that suppressed TFH cells still retaineda TFH-like transcriptional program, single sample gene set enrichmentanalysis (ssGSEA) was performed in which transcriptional states betweenactivated and suppressed TFH cells was compared with publishedtranscriptional signatures of TFH cells (from the Broad immSig C7collection). It was found that suppressed TFH cells qualitatively stillretained their TFH-like transcriptional signature suggesting that thesecells are not being converted to a different cell type duringsuppression and still have a TFH-like program.

Next whether B cells, similar to TFH cells, retain their effectorprogram during TFR cell suppression was determined. When B cell effectorgenes (from a curated list) in activated or suppressed B cells werecompared, lower expression of transcripts was found for antibodyisotypes including Ighg1 (IgG1, the dominant IgG isotype in theseassays), Ighg2c and Igha (FIG. 2F—FIG. 2G). Ighg2b transcripts wereupregulated upon suppression, however IgG2b was not increased by ELISAmeasurements in these assays. Three of the most downregulatedtranscripts in B cells upon TFR suppression were Pou2af1 (which encodesa transcription factor that is essential for GC B cell formation), Xbp1(which encodes a regulator of protein folding and ER stress which isimportant for secretion of antibody by plasma cells) and Aicda (whichencodes AID, an enzyme responsible for initiation of class switchrecombination). Despite these dramatic changes in genes important forGC/plasma cell function, most other B cell effector genes were notchanged in expression.

To determine if suppressed B cells still maintained an activated GC Bcell transcriptional signature despite changes in a small subset ofeffector genes, ssGSEA analysis was performed. When the activated andsuppressed B cells (along with GC B or naïve B sorted from immunizedmice) were compared, it was found that suppressed B cells still mostlymaintained their GC signature (FIG. 2H). Therefore, although suppressedTFH and B cells demonstrate downregulation of genes encoding effectormolecules (IL-4 and IL-21 in TFH, and IgG1, Xbp1, Pou2af1 and AID in Bcells), these cells still maintain a transcriptional signature similarto effector cells. Taken together, these data indicate that TFR cellsallow B and TFH cells to maintain an activated transcriptional signatureduring suppression but downregulate key effector molecules that areimportant for downstream effector function, suggesting that TFRsuppression is targeted to specific molecules.

To determine if any non-effector subset related pathways were altered inB and TFH cells during suppression basic GSEA was performed utilizingthe hallmarks, gene ontology and transcription factor gene sets from theBroad Institute. It was found that activated B cells showed strongenrichment of gene sets for Myc targets, MTORc1 signaling, oxidativephosphorylation and glycolysis compared to suppressed B cells (Table 1).Activated TFH cells also showed enrichment of E2F targets, glycolysisand MTORc1 signaling compared to suppressed TFH cells, however thisenrichment was not as strong as in B cells. Few gene sets were detectedthat enriched in suppressed B cells compared to activated B cells, withthe exception of interferon alpha response and G protein signalingcoupled to cAMP.

TABLE 1 Collection Gene Set Size NES FDR q-val Enriched in Act B vs.Supp B Hall (50) HALLMARK_MYC_TARGETS_V1 196 2.7671254 <0.0001HALLMARK_MYC_TARGETS_V2 58 2.3868976 <0.0001 HALLMARK_MTORC1_SIGNALING192 2.346688 <0.0001 HALLMARK_E2F_TARGETS 193 2.2503338 <0.0001HALLMARK_OXIDATIVE_PHOSPHORYLATION 191 2.1517582 <0.0001HALLMARK_UNFOLDED_PROTEIN_RESPONSE 111 2.1171036 <0.0001HALLMARK_GLYCOLYSIS 192 1.8493669 0.00031 HALLMARK_G2M_CHECKPOINT 1961.6099535 0.00383 HALLMARK_DNA_REPAIR 138 1.505335 0.01441HALLMARK_FATTY_ACID_METABOLISM 147 1.500412 0.01398 GO (1011) NUCLEOLUS110 2.0671701 0.00094 MITOCHONDRION 319 2.06659 0.00047MITOCHONDRIAL_PART 138 2.0225444 0.00129 RIBONUCLEOPROTEIN_COMPLEX 1421.9865174 0.00264 RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS_AND_ASSEMBLY 811.9715921 0.00249 PROTEASOME_COMPLEX 22 1.9145986 0.00636 RNA_SPLICING89 1.9071435 0.00599 TRANSLATION_INITIATION_FACTOR_ACTIVITY 21 1.88953540.00679 RNA_PROCESSING 166 1.883764 0.00656RIBOSOME_BIOGENESIS_AND_ASSEMBLY 18 1.8799101 0.00648 ISOMERASE_ACTIVITY35 1.8725868 0.00701 NUCLEOLAR_PART 18 1.8698697 0.00651MITOCHONDRIAL_MATRIX 45 1.8656288 0.00660 MITOCHONDRIAL_LUMEN 451.8638681 0.00626 TF (773) V$MYC_Q2 169 1.7301639 0.02973SGCGSSAAA_V$E2F1DP2_01 153 1.6884224 0.02908 V$E2F1_Q3 219 1.6836510.01995 V$E2F_Q5 214 1.6622303 0.02027 V$E2F4DP1_01 216 1.63781380.02317 V$E2F1_Q6 214 1.6301547 0.02114 V$MYCMAX_01 230 1.61620860.02279 Enriched in Act Tfh vs. Supp Tfh Hall (50) HALLMARK_E2F_TARGETS193 1.9549149 <0.0001 HALLMARK_HYPOXIA 193 1.8284913 0.00152449HALLMARK_G2M_CHECKPOINT 196 1.7426534 0.00319641 HALLMARK_GLYCOLYSIS 1921.7223264 0.00311881 HALLMARK_MTORC1_SIGNALING 192 1.709111 0.00276171

Example 3—TFR Suppression Alters the Myc and MTOR Pathways in B Cells

Whether Myc pathway genes were altered in B cells upon TFR suppressionwas determined since it was one of the most downregulated gene sets insuppressed B cells. Almost all Myc target genes in B cells showedevidence of downregulation at the transcriptional level during TFRsuppression (FIG. 5A). To determine if suppressing Myc in activated Bcells could recapitulate TFR suppression, in vitro suppression assayswere performed in which B cells were cultured with TFH cells, TFH andTFR cells, or TFH cells and the Myc inhibitor 10058-F4 (F4w). In theseassays, TFH cells stimulated robust class switch recombination to IgG1which was almost completely suppressed by the addition of TFR cells(FIG. 5B). Addition of the Myc inhibitor to the activated culture(B+TFH) resulted in a slight diminishment of class switch recombination.When the culture supernatants from these experiments were analyzed, itwas found that the Myc inhibitor robustly attenuated the amount ofsecreted antibody even greater than TFR cells (FIG. 5C). Therefore,inhibiting the Myc pathway results in suppression of class switchrecombination and antibody secretion.

Since the Myc pathway may be a key pathway in B cells that is modulatedduring TFR suppression, whether overexpression of Myc could cause Bcells to become resistant to TFR suppression was determined. WT orIgh-Myc (i.e. Eμ-Myc, Myc overexpressing) mice were cultured with TFHand TFR cells. Interestingly, Myc overexpression did not result inrescue of class switch recombination nor secreted antibody (FIG. 5D andFIG. 5E). However, GL7 expression in B cells was partially rescued inconditions of Myc overexpression, suggesting that Myc overexpression canprevent some suppression by TFR cells, although this may be minor. Takentogether, these data demonstrate that TFR cells suppress the Myc pathwayin B cells which may be partially responsible for defective antibodyproduction.

The mTOR pathway promotes protein synthesis during activation and hasbeen linked to enhancing cellular metabolism. Since evidence of themTORc1 pathway being downregulated at the transcript level in both B andTFH cells during TFR suppression (FIG. 4A) was found, whether blockingthe mTOR pathway could lead to suppression of antibody production wasdetermined. In vitro cultures of B and TFH cells were performed alongwith either the mTORc1 inhibitor rapamycin or TFR cells. Addition ofrapamycin to cultures resulted in severely diminished class switchrecombination as well as antibody production in similar magnitude asaddition of TFR cells (FIG. 6 B and FIG. 6C). Similar results were alsoobtained when the mTORc1/mTORc2 inhibitor PP242 was used (FIG. 6D andFIG. 6E). Therefore, inhibiting the mTOR pathway results in suppressionof class switch recombination and antibody production, similar to TFRcells. Akt can act both upstream and downstream of mTOR to mediateactivation signaling. When Akt was inhibited with an Akt1/2 inhibitor inthe B and T cell cocultures, it was found that inhibiting Aktsurprisingly caused an increase in class switch recombination (FIG. 6F).However, Akt inhibition resulted in diminishment of antibody secretionin coculture experiments. Taken together, these data indicate thatsuppressing the PI3K/Akt/mTOR pathway can result in suppression ofTFH-mediated B cell antibody production with a similar magnitude andfeatures of TFR mediated suppression.

Example 4—TFR Cells Suppress B Cell Metabolism

Whether TFR suppression of B and TFH cells resulted in alteredmetabolism was determined since the GSEA analysis demonstrateddownregulation of genes associated with glycolysis, oxidativephosphorylation, Myc and mTOR pathways. First a general comparison ofmetabolic pathways using RNA-seq data was performed comparing activatedor suppressed B cells (generated in FIG. 2A—FIG. 2H) by averagingexpression values of genes encoding key enzymes within individualpathways. Evidence of downregulation of a number of metabolic pathwayswas found including serine biogenesis, purine metabolism, 1-carbonmetabolism, TCA cycle, electron transport chain (which is involved inoxidative phosphorylation) and glycolysis (FIG. 7A). The only pathwaythat gave any indication of being increased in B cells upon suppressionwas fatty acid oxidation. Nevertheless, this data suggests that a numberof metabolic pathways are downregulated in B cells upon TFR suppression.To better visualize the complex interactions of a subset of thesepathways, a metabolic map of key intermediates in glycolysis, serinemetabolism, 1-carbon metabolism, purine metabolism and the TCA cycle wasmade. A number of key enzymes were found within these pathways includingenzymes that affect multiple pathways (FIG. 7B). Therefore, instead ofTFR cells suppressing one single metabolic pathway, this data suggeststhat TFR cells attenuate many different metabolic pathways as a part ofsuppression

The effects of suppression by TFR cells on glycolysis was assessed,since this pathway is essential for antibody production. Firstexpression of the glucose transporter Glut1 in B cells suppressed by TFRcells was compared. TFR cells (but not Treg cells) suppressed Glut1expression in B cells (FIG. 20), which suggested that the TFR cellssuppressed B cell glycolysis. The suppression of Glut1 expression (andCSR) in B cells by TFR cells was not due to an increase in the abundanceof non-dividing cells (which have low expression of Glut1), becausecomparison of B cells that had undergone the same number of celldivisions revealed diminished Glut1 expression and CSR in the suppressedB cells (FIG. 21 and FIG. 39A-FIG. 39E). In addition, the suppression ofCSR and metabolism by TFR cells occurred before the changes in B cellproliferation; when B cells were analyzed that had been added toactivated or suppressed cultures and harvested 20 h later (before thefirst cell division), B cells in suppressed cultures had lowerexpression of Glut1 and IgG1 than that of B cells in activated cultures(FIG. 22 and FIG. 39A-FIG. 39E). These studies indicated a decoupling ofCSR and metabolism from proliferation and demonstrated that thesuppression of CSR and metabolism in B cells by TFR cells could occurindependently of changes in proliferation. TFR cells (but not Tregcells) also caused lower expression of Glut1 in TFH cells (FIG. 23).

Whether or not metabolic pathways such as glycolysis were altered insuppressed B and TFH cells was confirmed. Glut1 is one of the mostimportant transporters for glucose and is a marker for glycolytic cells.When Glut1 expression was measured in B and TFH cells from activated orsuppressed cultures, it was found that TFR cells suppressed Glut1expression in both B and TFH cells suggesting that TFR cells suppressglycolysis in both B and TFH cells (FIG. 7C). To determine if B and TFHcells utilized less glucose in the suppressed cultures glucose from theculture supernatants was analyzed. It was found that in cultures of TFHand B cells, large amounts of glucose were utilized, which was decreasedstrongly with the addition of TFR cells (FIG. 7D). Lactate is generatedas a byproduct of glycolysis. When lactate production was measured inthe culture supernatants, large amounts of lactate were produced whenTFH cells were added to B cells, and that this lactate production wasseverely attenuated with TFR cells were additionally added (FIG. 7E).The suppression of lactate production was unique to TFR cells, asICOS-CXCR5− Tregs from the same lymph node were not able to potentlysuppress lactate production. In addition to glucose, glutamineutilization was also suppressed by TFR cells, which correlated with thedecreased glutaminolysis transcriptional signature that was measured byRNA-seq (FIG. 7F).

To determine if inhibiting glycolysis could recapitulate TFRsuppression, cultures of B and TFH cells were performed with theaddition of 2-deoxyglucose (2DG), a glucose analog that blocksglycolysis. When 2DG was added to activated cultures, a robustsuppression of antibody production was found, similar to TFR suppression(FIG. 7G and FIG. 24). Similar results were found when 2-nitroproprionicacid (NPA) was added which inhibits the TCA cycle. However, the additionof dichloroacetate (DCA), which shifts metabolism from glycolysis tooxidative phosphorylation, did not alter antibody production. This datasuggests that B cells can use multiple pathways of energy utilizationand when one pathway is strongly inhibited, it results in attenuation ofantibody production similar to suppression by TFR cells.

Next it was determined if the TFR cells also potently suppress serine,purine and 1-carbon metabolism since all key enzymes (with the exceptionof Mthfs) within this pathway have a lower transcript abundance in Bcells upon TFR suppression (FIG. 7H). Reduced expression of genesencoding products involved in one-carbon metabolism in B cellssuppressed by TFR cells was not due to altered proliferation, becausethe expression of Shmt1 and Shmt2 (a cytosolic enzyme and mitochondrialenzyme, respectively, in one-carbon metabolism that are upregulatedwithin hours of lymphocyte activation32) were attenuated before thefirst cell division (FIG. 25). Inhibitors of purine metabolism have beenused clinically in the context of autoimmunity to inhibit antibodyproduction. Therefore, whether inhibitors of purine metabolism couldrecapitulate TFR suppression in vitro was determined. Methotrexate(MTX), a purine synthesis inhibitor, was added to cultures of B and TFHcells and found that MTX robustly suppresses antibody production invitro even more so than TFR cells (FIG. 7I). Since methotrexate may haveaffects beyond inhibiting purine metabolism, an additional purineinhibitor azathioprine (AZA) was used. Addition of AZA to B and TFHcultures resulted in robust suppression of antibody secretion similar toMTX which was stronger than suppression by TFR cells alone (FIG. 7J).Both MTX and AZA also potently suppressed class switch recombination ofB cells similar to TFR cells. Taken together these data demonstrate thatTFR cells suppress multiple metabolic pathways in B cells and potentlysuppressing these pathways results in similar suppression of antibodyproduction by B cells.

Example 5—TFR Suppression of B Cells Results in Prolonged Inhibition andEpigenetic Changes

Next it was determined whether suppressed B cells were capable ofbecoming activated cells or whether TFR suppression elicits a longlasting suppression that continues after TFR cells are no longerpresent. To test this, the in vitro suppression assay was adapted. Theactivated or suppressed B and TFH cultures were set-up and after 3 days,sorted the activated or suppressed B cells. These B cells were culturedwith new TFH cells in a secondary culture, and after 6 days analyzed thecultures (FIG. 8A). First, TFH cells were measured from these cultures.It was found that TFH cells cultured with suppressed B cells had Ki67and Bc16 costaining suggesting that TFH cells from these cultures wereactivated by suppressed B cells (FIG. 8B and FIG. 26). However, whenintracellular IgG1 in B cells from these cultures was analyzed, it wasfound that suppressed B cells restimulated by TFH cells were stillseverely defective in the ability to undergo class switch recombination(FIG. 8C). Since the previous examples suggest that TFR cells suppress Bcell class switch recombination through downregulating metabolism, itwould be expected that the suppressed B cells that were reactivatedwhich have defective class switch recombination would also have defectsin metabolism. To answer this question, Glut1 expression was analyzed insuppressed B cells that were reactivated with TFH cells and found thatalthough Glut1 expression was higher than suppressed B cells from theprimary culture, it was much lower than activated B cells (FIG. 8D).Additionally, when glucose uptake from cultures was measured, it wasfound that suppressed B cells with reactivation cultures hadsubstantially less glucose utilized (FIG. 8E). Together these dataindicate that B cells suppressed by TFR cells have defects in classswitch recombination and metabolism which persists after TFR cells areno longer present.

The findings that suppressed B cells maintain defective class switchrecombination after TFR cells point to modification of the B cells. Onepossible explanation of this data is that TFR cells may cause epigeneticmodifications to B cells during suppression and that these epigeneticmodifications last longer than the presence of TFR cells. Therefore,chromatin accessibility was assessed utilizing assay fortransposase-accessible chromatin using sequencing (ATAC-seq) todetermine if any key B cell effector or metabolic genes showed anyevidence of changes in accessibility, possibly due to epigenetic changeselicited by TFR cells. The in vitro suppression assay was performed asin FIG. 8A, except using NP-OVA instead of anti-CD3 and sorted activatedand suppressed B cells 3 days after culture. 646 genes were found thatdemonstrated a statistical downregulation in accessibility in suppressedB cells compared to activated B cells (FIG. 8F). Of these genes, 43 alsohad lower expression at the RNA level. Aicda and Pou2af1, two essentialB cell function genes whose transcripts were highly downregulated at theRNA level also showed evidence of chromatin inaccessibility by ATAC-seqsuggesting epigenetic modification (FIG. 8G). The Aicda locus showedless accessibility in a region ˜8 kb upstream of the Aicda TSS. Thisregion is a known enhancer region where NF-kb, Stat6 and C/EBPtranscription factors bind and is critical for AID expression20. Twopeaks were found that showed evidence of inaccessibility in the Pou2af1locus; one in close proximity to the TSS and one in an intronic regionin between exons 1 and 2. Therefore, AID and Pou2af1, two genes that areessential for class switching and GC formation, may be inhibited byepigenetic modification elicited by TFR suppression which may explainsuppression of B cells after TFR cells are no longer present.

To explore how the genes identified are regulated, the ATAC-seq data wasoverlaid with the ‘B cell regulome’ (a collection of confirmedinteractions of promoters with long-range enhancers in B cells) definedby ChIA-pet techniques. The Aicda locus showed less accessibility insuppressed B cells than in activated B cells in two regions, one ˜8kilobases (kb) and another ˜21 kb upstream of the Aicda transcriptionalstart site (TSS) (FIG. 27). These enhancer regions are essential for AIDexpression33,34. Seven putative enhancer regions in the Myc locus wereidentified that were less accessible in B cells suppressed by TFR cellsthan in activated B cells (FIG. 28). One peak was found that was lessaccessible in the Pou2af1 locus that was located in an intronic regionin between exon 1 and exon 2 (FIG. 29). Many of the less-accessibleregions in suppressed B cells were not at the TSS but were at sites oflong-range enhancers (FIG. 28 and FIG. 29). When the distribution of allATAC-seq regions was quantified relative to the location of the TSS, theless-accessible regions in B cells suppressed by TFR cells tended to befurther away from the TSS than were all regions identified by ATAC-seq(FIG. 30). These data indicated that genes encoding products criticalfor B cell function, but not those encoding key metabolic enzymes,showed evidence of epigenetic regulation during suppression by TFRcells.

Interestingly, none of the key metabolic enzymes that were downregulatedby RNAseq (see FIG. 7B) showed any clear evidence of DNAinaccessibility. However, 3 mitochondrial/metabolic genes did showevidence of inaccessibility; Atp5f1, Acadm and Auh. Atp5f1 functions inthe electron transport chain during oxidative phosphorylation, a pathwaysuppressed globally at the RNA level. Acadm functions in mitochondrialfatty acid beta-oxidation pathway. Auh encodes an enzyme which functionsto breakdown leucine and can bind to AU rich elements (AREs) in RNA.Taken together, these data indicate that select B cell function genesshow evidence of epigenetic regulation during TFR suppression and with afew exceptions, metabolic genes are not epigenetically modulated bychromatin remodeling. This data suggests that TFR suppression primarilyaffects epigenetic modification of AID and Pou2af which may alterdownstream B cell function and metabolism.

Example 6—IL-21 can Overcome TFR Mediated Suppression of B CellMetabolism and Antibody Production

The data indicates that TFR cells suppress B cells through targeteddownregulation of B cell function genes and altered metabolism. It ispossible that B cell function genes and multiple metabolic pathwayscooperate to induce class switch recombination and antibody productionin B cells. TFR suppression of B cells was not able to be rescuedthrough bypassing any single metabolic pathway (FIG. 7A-FIG. 7J)suggesting that TFR suppression of multiple metabolic pathways and/or Bcell genes contributes to suppression. Therefore, to determine ways toovercome suppressed B cells therapeutically, it is possible that both Bcell genes and metabolism would need to be energized to overcomesuppression. IL-21 is a cytokine which is essential in the germinalcenter reaction which is potently suppressed by TFR cells. IL-21 canalso control metabolic processes in fat tissue, and has been shown toinhibit Treg suppression of effector cells. When IL-21 was added tosuppression assays, the attenuation in proliferation of B cells mediatedby TFR cells was rescued (FIG. 11A). Moreover, class switchrecombination was much higher in suppressed conditions with the additionof IL-21, however, this did not quite reach activated culture levels(FIG. 11B). Addition of IL-21 to suppressed cultures mostly rescued theamount of secreted antibody compared to activated cultures, a resultthat did not occur when IL-4 was added (FIG. 11C). However, IL-6,another Stat3 signaling cytokine, was also able to rescue thesuppression of antibody production.

Since metabolism is essential to facilitate B cell effector functionsand is regulated by TFR cells, the metabolic potential of B cells wasassessed in suppressed cultures with the addition of IL-21. Glut1expression was completely rescued on B cells when IL-21 was added tosuppressed cultures (FIG. 11D). Similarly, Glut1 expression on TFH cellswas rescued when IL-21 was added to suppressed cultures. Glucoseconsumption in the culture was almost completely rescued when IL-21 wasadded to suppressed cultures (FIG. 11E). IL-21 and IL-6 were also ableto substantially (although not completely) rescue lactate production insuppressed cultures (FIG. 11F). Therefore, addition of IL-21 can rescuethe glycolytic function of suppressed B cells. It is possible that IL-21rescues antibody production primarily through enhancing metabolism. Todetermine if enhanced glycolysis was required for the IL-21 rescue ofantibody production in suppressed cultures, glycolysis was blocked todetermine if antibody responses could still be rescued in the absence ofenhanced metabolism. Blocking glycolysis resulted in the IL-21 not beingable to rescue suppression (FIG. 11G). Therefore, IL-21 renders B cellsresistant to TFR mediated suppression primarily by enhancing metabolism.

In order to determine which B cell function genes were rescued at thetranscriptional level, RNA-seq transcriptional analysis was performed onB cells from activated cultures, from suppressed cultures, andsuppressed cultures supplemented with IL-21. When B cell function geneswas assessed (as in FIG. 2G) in suppressed vs. suppressed plus IL-21cultures, only transcripts for the individual IgG isotypes (Ighg1,Ighg2c, Ighg2b, Igha) showed evidence of significant upregulation withaddition of IL-21 (FIG. 11H). Only 12 genes were expresseddifferentially in B cells from suppressed cultures versus those from‘IL-21 rescue’ cultures and also in B cells from suppressed culturesversus those from activated cultures, and of these genes, only Ighg1 andIghg2c were ‘rescued’ with IL-21 (FIG. 31) Interestingly, the three mostsuppressed B cell function genes during TFR suppression, Aicda, Xbp1 andPou2af1, did not show any evidence of rescue with IL-21. In the case ofAicda and Pou2af1, it is possible that this may be due to the epigeneticmodification of these gene loci by TFR cells, however this was nottested directly.

Next whether metabolic pathways other than glycolysis could be rescuedtranscriptionally was determined. ssGSEA was performed on our RNA-seqsamples and evidence of some rescue of many metabolic pathways with theaddition of IL-21 (FIG. 11I) was found. Therefore, IL-21 overcomes TFRsuppression by stimulating B cells as well as metabolic pathways.

Whether IL-21 restored antibody production by acting directly on B cellswas determined. Suppression assays were performed using B cells lackingthe receptor for IL-21 (Il21r−/−). Although baseline antibody responseswere lower in cultures of Il21r−/− B cells with TFH cells than in thoseof Il21r+/+B cells with TFH cells, no evidence was found that antibodyresponses were restored in suppressed cultures by the addition of IL-21(FIG. 32). Loss of IL-21R did not abolish the increase in the number ofB cells observed in suppressed cultures after the addition of IL-21 butdid prevent the restoration of CSR and Glut1 expression (FIG. 40A-FIG.40C). Since upregulation of GL7 is a robust indicator of B cellactivation, its expression in suppressed cultures containing eitherIl21r+/+B cells or Il21r−/− B cells and supplemented with IL-21 wascompared. IL-21 restored GL7 expression when Il21r+/+B cells werepresent but not when Il21r−/− B cells were present (FIGS. 33 and 34),which suggested that signaling through IL-21 into the B cells wasessential for the restoration of B cell activation.

Since IL-21 could be affecting the TFH, B or TFR cell in the suppressedculture, whether the rescue of suppressed metabolism could be due to acombined effect of stimulating B cells and inhibiting TFR suppression(by acting directly on the TFR cell) was determined. When the TFR cellsfrom suppressed cultures with or without addition of IL-21 was analyzed,it was found that the TFR cells in cultures that contained IL-21 hadmuch less intracellular Ki67 staining suggesting that cell cycling isinhibited in TFR cells with the addition of IL-21 (FIG. 11J). Glut1expression was higher in TFR cells in the presence of IL-21 than in itsabsence (FIG. 35), which suggested that IL-21 was able alter themetabolism of TFR cells as well as their activation. Therefore, IL-21rescue of TFR cell suppression of B and TFH cells is the result ofmodulation of B cells as well as inhibiting TFR cells.

INCORPORATION BY REFERENCE

All publications, patents, and patent applications mentioned herein arehereby incorporated by reference in their entirety as if each individualpublication, patent or patent application was specifically andindividually indicated to be incorporated by reference. In case ofconflict, the present application, including any definitions herein,will control.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain usingno more than routine experimentation, many equivalents to the specificembodiments described herein. Such equivalents are intended to beencompassed by the following claims.

1-35. (canceled)
 36. A method of reducing immune suppressive activity ofTFR cells in adoptive immunotherapy, comprising contacting TFR cellsisolated from a subject with a cytokine in-vitro or ex-vivo, and whereinthe reduced immune suppressive activity results in a protective antibodyresponse, wherein the cytokine is IL-21 or IL-6.
 37. The method of claim36, wherein the reduced immune suppressive activity is characterized bya boost of antibody production as compared to native TFR cells.
 38. Themethod of claim 36, wherein the method comprises contacting the TFRcells isolated from a subject with IL-21.
 39. The method of claim 36,wherein the method comprises contacting the TFR cells isolated from asubject with IL-6.
 40. A composition comprising TFR cells, TFH cells,and a cytokine, wherein said composition has reduced immune suppressiveactivity, wherein the reduced immune suppressive activity results in aprotective antibody response, and wherein the cytokine is IL-21 or IL-6.41. The composition of claim 40, wherein the cytokine is IL-21.
 42. Thecomposition of claim 40, wherein the cytokine is IL-6.
 43. A vaccinecomposition comprising the composition of claim
 40. 44. A method oftreating an allergy in a subject, the method comprising administeringthe composition of claim
 40. 45. An adjuvant comprising a composition ofTFH cells and a cytokine, wherein the TFH cells have an enhancedstimulatory capacity, and wherein the cytokine is IL-21 or IL-6.
 46. Theadjuvant of claim 45, wherein the enhanced stimulatory capacity resultsin an increase in antibody production.
 47. The adjuvant of claim 45,wherein the cytokine is IL-21.
 48. The adjuvant of claim 45, wherein thecytokine is IL-6.
 49. The adjuvant of claim 45, wherein the TFH cellsare purified from the peripheral blood of a subject.
 50. A method ofboosting the antibody production in a subject in need thereof byadministering the adjuvant of claim 45 to the subject.